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Aldehyde dehydrogenases superfamily 
Aldehydes dehydrogenases (ALDHs) are known to be NAD(P)+ dependent 
enzymes responsible for the oxidation of a wide spectrum of aldehydes into their 
corresponding carboxylic acids[1]. Phylogenetic studies suggested that ALDHs 
derived from four ancestral genes that exist prior to the division between 
Eubacteria and Eukaryotes about 2 billion years ago[2]. The evolutionary history of 
ALDH genes started with diversifications and duplications occurred from 890 
million years ago to 70 million years ago[2]. The ALDH superfamily is represented 
across Archea, Eubacteria and Eukarya taxa with multiple genes, implying a 
critical role for these enzymes in the evolutionary history of many species[3]. The 
actual nomenclature of human ALDH superfamily was established during the 
Ninth International Symposium on Enzymology and Molecular Biology of 
Carbonyl Metabolism, held in 1998, in Varallo Sesia, Italy[1]. The ALDH 
superfamily comprises 19 functional protein-coding genes located on different 
chromosomes. ALDH isoforms belong to families from ALDH1 to ALDH9, 
ALDH16 and ALDH18 (Figure 1)[4], [5]. Human ALDHs are grouped in the same 
family by sharing more than 40% sequence identity, meanwhile they belong to the 
same subfamily when they exhibit more than 60% of amino acids identity[5]. The 
main biological role of ALDHs is regarded as being detoxifying enzymes, due to 
the ability to inactivate endogenous and exogenous toxic aldehydes. Nevertheless 





















Figure 1. Evolutionary tree for human aldehyde dehydrogenases with indication of chromosomal location and 
preferred substrate from Koppaka et al.[6]. 
 
ALDHs catalyze the conversion of exogenous and endogenous 
aldehydes 
Aldehydes are reactive electrophilic molecules with at least one hydrogen 
substituent on the carbonyl carbon at the end of the carbon chain. Aldehydes can be 
grouped in four large subclasses: short chain aldehydes, long chain alkanals, 
aromatic aldehydes and α,β-unsaturated aldehydes[7]. The anthropic activities such 
as combustion of hydrocarbon fuels, solvent utilization, air pollution, cigarette 
smoke, preservation of food and metabolism of drugs are the main causes of 
exogenous aldehydes formation. In addition, endogenous aldehydes are often by-




neurotransmitters catabolism, vitamins and steroids metabolism[8]. Cytotoxic 
endogenous and exogenous aldehydes are detoxified mainly through the oxidation 
catalyzed by ALDHs that prevents mutagenesis and cell death caused by DNA-
adducts and cross-linking of proteins, consequence of aldehydes reactivity[9], [10]. 
Besides their key role as detoxifying enzymes, ALDHs are important catalysts in 
the xenobiotic metabolism (Figure 2). The phase 1 of drug metabolism consists in 
the biotransformation of the pharmaceutical compound that involves the oxidation 














Figure 2. Schematic representation of the xenobiotic metabolism of drugs in humans. 
 
ALDHs are implicated both in the detoxification of cells and in important 
metabolic and signaling processes (Figure 3). Different ALDH isoforms catalyze 
the biosynthesis of physiologically relevant molecules involved in embryonic 


















Figure 3. Schematic representation of ALDHs catalytic activity and their role in cell detoxification and 
metabolism, from Vasiliou et al.[5]. 
 
Representative isoforms of human ALDH superfamily and their 
biological roles 
The 19 ALDH isoforms composing the ALDH superfamily are listed in Table 1 
with a brief description of the main characteristics for each isoforms.  
ALDH1A1, ALDH1A2 and ALDH1A3 are the three known isoforms of the 1A 
subfamily participating in the biosynthesis of retinoic acid (REA), a morphogen 
molecule that regulates embryonic development and cellular differentiation. By 
oxidizing retinaldehyde to retinoic acid the three ALDH1A isoforms are essential 






amino acid identity [4]. A database and website (www.aldh.org)
maintained by the laboratory of Dr. Vasilis Vasiliou at the
University of Colorado Denver is dedicated to providing a detailed,
up-to-date resource for the ALDH gene superfamily [6].
The eukaryotic ALDH gene superfamily currently consists of 24
families that contain putatively functional genes with distinct
chromosomal locations. It is anticipated that the number of ALDH
families will expand after the inclusion of the bacterial ALDHs
(Vasiliou et al., unpublished). Human genes are found in ALDH1–
9, ALDH16 and ALDH18 families, which also contain genes from
other species including plant and fungi [7].
1.3. ALDH families
The ALDH1A subfamily comprises ALDH1A1, ALDH1A2 and
ALDH1A3, all of which synthesize RA from retinaldehyde and, as
such, are crucial in regulating RA signaling [4]. These isozymes
have a high affinity for the oxidation of both all-trans- and
9-cis-retinal and exhibit a Km for these molecules in the low micro-
molar range [8]. Although ALDH2 officially qualifies as a member
of the ALDH1 family, its longstanding name of ‘‘ALDH2’’ (associated
with ethanol metabolism) has been grandfathered into the ALDH
nomenclature system based on evolutionary divergence. ALDH2
is a mitochondrial enzyme that is primarily involved in the metab-
olism of acetaldehyde generated during alcohol metabolism [1].
ALDH1B1, a mitochondrial enzyme very similar to ALDH2 (75%
identical to ALDH2), also contributes to acetaldehyde oxidation,
albeit with lower affinity than ALDH2 [9]. ALDH1B1 is a potential
colon cancer biomarker [10]. The ALDH1L1 gene codes for the cyto-
solic 10-FTHF dehydrogenase (FDH), which converts 10-formyltet-
rahydrofolate (10-FTHF) to tetrahydrofolate [11]. The ALDH1L2
gene is very similar to ALDH1L1 and encodes the mitochondrial
FDH that has enzymatic properties similar to its cytosolic counter-
part. Unlike ALDH1L1, ALDH1L2 does not metabolize short-chain
aldehyde substrates [12]. The ALDH3A subfamily contains the di-
oxin-inducible ALDH3A1 and ALDH3A2 enzymes, both of which
are involved in the oxidation of medium- and long-chain aliphatic
and aromatic aldehydes [13,14]. The ALDH3B subfamily consists of
two structurally-related genes, ALDH3B1 and ALDH3B2. ALDH3B1
enzyme metabolizes aldehydes generated during lipid peroxida-
tion [15]. As yet, no functional data for ALDH3B2 gene product
exists.
The mitochondrial ALDH4A1, also known as pyrroline-5-car-
boxylate (P5C) dehydrogenase and glutamate-c-semialdehyde
dehydrogenase, catalyzes the irreversible NAD+-dependent conver-
sion of P5C to the neurotransmitter, glutamate [16]. The ALDH5A1
isozyme, also known as succinic semialdehyde (SSA) dehydroge-
nase, catalyzes the NAD+-dependent conversion of SSA to succinate
in the last step GABA catabolism [17]. ALDH6A1 is a mitochondrial
enzyme also known as acetyl CoA-dependent methylmalonate
semialdehyde (MMS) dehydrogenase. ALDH6A1 is involved in
valine and pyrimidine catabolism and catalyzes the oxidative
decarboxylation of malonate semialdehyde and MMS to acetyl-
CoA and propionyl-CoA, respectively [18]. Human ALDH7A1 has a
primary role in the pipecolic acid pathway of lysine catabolism,
catalyzing the oxidation of alpha-aminoadipic semialdehyde
(AASA) to alpha-aminoadipate [3,19]. ALDH8A1 is a cytosolic en-
zyme that appears to m tabolize retinaldehyde to retinoic acid
[20,21]. ALDH9A1 codes for an enzyme that participates in the
me abolism of c-aminobutyraldehyde and aminoaldehydes de-
rived from polyamines [22]. The ALDH16A1 gene encodes an
802-amino acid protein with as-yet unknown function that most
likely does not possess catalytic activity (Vasiliou et al., in this vol-
ume). ALDH16A1 is a novel and rather unique member of the ALDH
superfamily in that it contains two ALDH active site domains (as
opposed to one in the other members f the superfamily), four
transmembrane domains and a coiled-coil domain. Interestingly,
the ALDH16 enzyme active site in frog and many invertebrates
(e.g. sea squirt, sea anemone, sea urchin, lancelet, and Trichoplax
adhaerens), as well as in bacteria, contains the catalytically-
important cysteine residue (Cys-302); in contrast, this residue is
absent from the mammalian and fish orthologous protein. The
Vasiliou et al. chapter in this issue describes this ALDH as a protein
interacting molecule [23].
The ALDH10 family contains plant genes encoding enzymes
known as aminoaldehyde dehydrogenases (AMADHs), 4-aminobu-
tyraldehyde dehydrogenases, 4-guanidinobutyraldehyde dehydro-
genases, and betaine aldehyde dehydrogenases (BADHs). The
ALDH11 family of genes codes for the cytosolic non-phosphorylat-
ing glyceraldehyde 3-phosphate dehydrogenases (GAPNs). These
enzymes catalyze the irreversible NADP+-dependent oxidation of
glyceraldehyde 3-phosphate (GAP) to 3-phosphoglycerate and
NADPH [24]. The ALDH12 family contains mostly plant genes
encoding D-1-pyrroline-5-carboxylate dehydrogenases (P5CDH),
enzymes involved in the conversion of proline and arginine to
glutamate [25]. The ALDH13 family contains a gene found only in
Entamoeba histolytica most likely involved in acetaldehyde
metabolism [26]. The ALDH14 and ALDH15 families contain yeast
and fungi ALDHs [27]. ALDH14 encodes a mitochondrial enzyme
that appears to be similar to the microsomal ALDH3A2 [5]. The
ALDH15 gene appears to be similar to plant ALDH21 and may play
a role in protection against oxidative stress [25]. The ALDH17 gene
Fig. 1. Illustration of ALDH catalytic activity.




Table 1. List of ALDH isoforms with brief description of localization, substrate preference and other functions, 





















ALDH1A1 is a homotetramer cytosolic enzyme distributed in retina, eye lens, 
lung, kidney, liver and brain. ALDH1A1 represent 2-3% of cytosolic proteins in 
retina and it is important to protect the eye from UV - damage generated 
aldehydes[11]. ALDH1A1 is mainly involved in embryonic development and in the 
last years has been investigated for its role in cancer stem cell biology and 
chemotherapy resistance[11]. Hematopoietic progenitor cells expressing high levels 
of ALDH1A1 showed an increased tolerance to active metabolites of 
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Table 1
Human ALDH proteins.
ALDH Subcellular location Preferred aldehyde substrate Additional functions and
characteristics
ALDH1A1 Cytosol Retinal Ester hydrolysis; binds androgen,
cholesterol, thyroid, daunorubicin, and
flavopiridol; corneal and lens crystallin;
oxidizes DOPAL, acetaldehyde
ALDH1A2 Cytosol Retinal High affinity for LPO-derived aldehydes
ALDH1A3 Cytosol Retinal High affinity for LPO-derived aldehydes
ALDH1B1 Mitochondria Acetaldehyde May protect the cornea from UV-light
ALDH1L1 Cytosol 10-Formyltetrahydrofolate Binds acetaminophen
ALDH1L2 Unknown Unknown Induced by the anti-inflammatory agent
indomethacin
ALDH2 Mitochondria Acetaldehyde Ester hydrolysis; nitroglycerin
bioactivation, oxidizes LPO-derived
aldehydes; binds acetaminophen;
oxidizes DOPAL and DOPEGAL
ALDH3A1 Cytosol, nucleus* Aromatic, aliphatic aldehydes Ester hydrolysis; scavenges ROS; UV-
filter; corneal crystallin; oxidizes LPO-
derived aldehydes; regulation of cell-
cycle; inducted by PAHs
ALDH3A2 Microsomes, peroxisomes ‡ Fatty aldehydes Insulin regulates gene expression
ALDH3B1 Cytosol § Unknown Oxidizes LPO-derived aldehydes
ALDH3B2 Unknown Unknown Unknown
ALDH4A1 Mitochondria Glutamate γ-semialdehyde Ester hydrolysis; may mitigate oxidative
stress
ALDH5A1 Mitochondria Succinate semialdehyde May be involved in neurotransmission
efficiency
ALDH6A1 Mitochondria Malonate semialdehyde Esterase activity; only known human
CoA-dependent ALDH
ALDH7A1 Cytosol, nucleus, mitochondria¶ α-Aminoadipic semialdehyde Closely related to plant osmoregulatory
protein; may regulate cell cycle
ALDH8A1 Cytosol Retinal Oxidizes LPO-derived aldehydes and
acetaldehyde
ALDH9A1 Cytosol γ-Aminobutyraldehyde Oxidizes betaine, acetaldehyde and
DOPAL; involved in carnitine
biosysnthesis; esterase activity
ALDH16A1 Unknown Unknown Unknown
ALDH18A1 Mitochondria Glutamic γ-semialdehyde Unknown
*
While predominantly cytosolic, ALDH3A1 is also found in the nucleus.
‡
A variant of ALDH3A2, FALDHv, is believed to be localized to the peroxisomes.
§
Marchitti SA, Vasiliou V. unpublished data.
¶
Brocker C, Cantore M, Pappa A, et al. unpublished data.




overexpress ALDH1A1 demonstrated an enhanced resistance to doxorubicin and 
paclitaxel[13]. ALDH1A2 is the second isoform involved in REA biosynthesis. It is 
expressed in various embryonic tissues as a cytosolic homotetramer and it regulates 
early heart development in mice[4]. Furthermore human spina bifida disease is 
significantly associated with ALDH1A2 single nucleotide polymorphisms[14]. 
ALDH1A3 is the third isoform implicated in REA signaling pathway and its role 
has been demonstrated crucial in nasal development and more general in 
embryonic development[15]. ALDH1A3 is expressed in fetal nasal mucosa, kidney, 
breast, stomach and salivary gland and it is involved in the development of eye, 
olfactory bulbs, hair follicles, forebrain and cerebral cortex[4]. Mutation in human 
ALDH1A3 gene has been identified as the major cause of 
microphtalmia/anophtalmia[16]. Recently the isoenzyme is assuming a central role 
in the biology of different cancers in relation to its overexpression in ALDH- 
positive cancer stem cells. 
ALDH1L1 is a cytosolic multi domain homotetramer important for the conversion 
of 10-formyltetrahydrofolate to tetrahydrofolate (THF). THF is an important 
metabolite in the dietary folate, in one-carbon metabolism and in the purine 
biosynthesis[17].  
ALDH2 is a mitochondrial homotetramer responsible for the conversion of 
acetaldehyde to acetic acid. ALDH2 is the main enzyme of the ethanol metabolism 
and its well-known dominant allelic variant ALDH2*2 is the main cause of 
alcoholic liver disease and cirrhosis in Asian population [18], [19]. 
ALDH3A1 detoxifies aromatic and medium-chain aldehydes derived from lipid 
peroxidation[20]. ALDH3A2 is a microsomal homodimer that catalyzes the 
oxidation of fatty aldheydes and it is part of the fatty alcohol:NADoxidoreductase 
enzyme complex[21]. Deletions at the first five exon of the enzyme are correlated 




ALDH4A1 participates in glutamate biosynthesis and proline degradation by 
promoting the conversion of pyrroline 5-carboxylate to glutamate[23]. Mutations in 
its coding gene are responsible of type II hyperprolinemia[24]. 
ALDH5A1 is a mitochondrial homotetramer, also known as succinic semialdehyde 
dehydrogenase (SSADH) that is implicated in the catabolism of γ-aminobutyric 
acid (GABA) by converting succinic semialdehyde to succinate[25]. The 4-
hydroxybutyric aciduria, a neurological autosomal disorder, is a disease related to 
ALDH5A1 malfunction[26].  
ALDH6A1 is involved in the valine and pyrimidine catabolism. The enzyme 
catalyzes the irreversible oxidative decarboxylation of malonate and 
methylmalonate semialdehydes to acetyl- and propionyl-CoA. Mutations to 
ALDH6A1 are responsible of dysmielination and methylmalonate aciduria[27]. 
ALDH7A1 is a homotetramer found both in cytosol and mitochondria. The enzyme 
participates to the lysine metabolism and mutations on ALDH7A1 gene cause 
pyridoxine dependent epilepsy[28], [29]. 
ALDH8A1 is the only isoform outside the ALDH1A subfamily involved in the 
retinoic acid metabolism. ALDH8A1 has the characteristic to prefer 9 cis-retinal 
substrate compared to all trans-retinal, showing a 40 times higher affinity[30]. 
ALDH9A1 is a key enzyme in the alternate metabolism of GABA. The cytosolic 
tetramer of ALDH9A1 oxidizes γ-aminobutyraldehyde to GABA[31]. ALDH16A1 
is a recently discovered non-catalytic ALDH isoform. It has a preference for the 
NADP+ cofactor and seems to interact with maspardin, a protein responsible of 
spastic paraplegia[32]. ALDH18A1 is the second mitochondrial ALDH involved in 
the proline synthesis and it is a bifunctional enzyme that utilizes ATP and NADP 








Structural and functional aspects of ALDH 
ALDHs are built on three functional domains: the NAD+ binding domain at the N-
terminal, the catalytic domain and the oligomerization domain at the C-terminal 
(Figure 4)[34]. The global tertiary structure of ALDHs is conserved among isoforms 
across all families, and both the N-terminal and the C-terminal domains involve 
well-known and conserved amino acids in the binding of the cofactors and in the 












Figure 4. Structure of sheep liver cytosolic ALDH1A1 in complex with NAD+[34]. The α-helix, the β-sheets 
and the connecting loop composing the N-domain, the C-domain and the oligomerization domain are 
respectively showed in red, blue and yellow. 
 
ALDHs function as catalysts for the oxidation of aldehydes, although these 
enzymes are known to possess also an esterase activity. Beside the large 
differences in substrate selectivity, the ALDH superfamily shares the same 
catalytic mechanism. The only known exception is ALDH6A1 that uses CoA 
instead of NAD(P)+ as cofactor for the decarboxylation of malonate[36]. The 
aldehyde oxidation through ALDH catalysis is well described in the Figure 5 




ordered reaction in which the enzyme first binds the cofactor than allows aldehyde 
or ester to enter the catalytic site[37]. The nucleophilic attack on the substrate is 
operated by the active nucleophile C302 that is conserved among all the ALDHs 
(the numbering of amino acids is conventionally based on the mature human 
ALDH2). The thiol of the C302 is activated by a water-mediated proton abstraction 
operated by the highly conserved E268 that act as a general base[6]. The nucleophile 
C302 attacks the carbonyl carbon of the substrate driving through the formation of 
the thioemiacetal intermediate. The hydride ion transfer from the intermediate to 
the cofactor occurs on the C4 of the nicotinamide ring and it is stereospecific for 
the pro-R side[38]. After the hydride transfer, the E268 activates a second water 
molecule that is responsible of the hydrolysis of the thioester intermediate and the 
consequent release of the product. Simultaneously the reduced cofactor leaves the 
enzyme that is finally regenerated by the binding of a new NAD(P)+ molecule 
through the conserved residues E399 and K192[6]. Studies on ALDH three-
dimensional structure and its catalytic mechanism has been reported in three 
pivotal works on ALDHs[34], [35], [39]. Liu and collaborators focused on the different 
way ALDH binds NAD(P) respect to the typical binding of other enzymes sharing 
the Rossmann fold. Usually the pyrophosphate moiety of NAD closely interacts 
with the fingerprint sequence GlyXGlyXXGly that is located in the loop between 
the β1-αA motifs of the βαβ-conserved Rossmann fold domain. Instead, in ALDH 
the nucleotide cofactor binds between the β4-αD loop rather than in the canonical 
β1-αA and the pyrophosphates does not interact strongly with any residue (Figure 
6)[39]. In all the ALDH structures solved in complex with NAD, the cofactor lies in 
an hydrophobic pocket and it is more likely stabilized through hydrogen bonds 




















Figure 5. Description of ALDH catalytic mechanism by Koppaka et al.[6] 1: The enzyme binds the NAD(P) 
cofactor and E268 activate the water molecule responsible of the thiol deprotonation. 2: Nucleophilic attack of 
C302 on the carbonyl carbon of the aldehyde 3: Thioemiacetlal intermediate formation and concomitant 
hydride transfer to the NAD(P)+ cofactor 4: Activation of a water molecule through E268 and hydrolysis of the 
thioester 5: Release of the carboxylic acid and reduced cofactor. 
 
In the sheep liver ALDH1A1 structure, for the first time, was described the 
flexibility of the nicotinamide ring in complex with ALDH. The cofactor was 
found in two major conformations belonging to two different catalytic steps: the 
hydride transfer conformation, in which NAD+ is closer to the active site, ready to 
accept the hydride, and the release conformation where the reduced cofactor moved 
away from the catalytic site to make room for the product hydrolysis[34]. 
  
 
FIG. 3. A, mechanism of aldehyde oxidation. 1, activation of the catalytic Cys302 by the ordered water molecule and Glu268 through proton
abstraction. 2, nucleophilic attack on the carbonyl carbon of the aldehyde by the thiolate group of the catalytic Cys302. 3, formation of the tetrahedral
thiohemiacetal intermediate (deacylation) and hydride transfer from the tetrahedral thiohemiacetal intermediate to the pyridine ring of NAD!. 4,
hydrolysis of the resulting thioester intermediate. 5, dissociation of the reduced cofactor and subsequent regeneration of the enzyme by NAD! binding.
B, proposed mechanism of ester hydrolysis. 1, catalytic cysteine residue is activated by hydrogen abstraction from a basic residue (Glu268) in catalytic
site. 2, thiolate ion attacks the substrate p-nitrophenyl acetate leading to oxyanion intermediate formation. 3, the intermediate rearranges and
nitrophenolic group leaves. 4, Glu268 residue abstracts hydrogen from nearby ordered water molecule, making it a nucleophile. It attacks the carbonyl
in the thioacyl enzyme complex. 5, formation of the tetrahedral intermediate that again rearranges to release acetic acid and free enzyme.














Figure 6. Comparison of NAD binding mode between ALDH3 and alcool dehydrogenase (ADH). The ALDH3 
structure is reported as cartoon on the left side of the figure and it evidences how NAD binds between αD β4 
and αC of the Rossmann fold. In the ADH structure, reported as cartoon on the right side of the figure, NAD 
exhibits the classical binding between αA and β1 of the Rossmann fold. From Liu et al., 1997[39]. 
 
ALDHs are known to process a wide spectrum of substrates, albeit each isoform 
displays a major affinity for its “preferred” or natural substrate. Moore et al. 
compared ALDH1 and ALDH2 structures to identify mechanisms involved in 
substrate selectivity and affinity[34]. The authors highlight the determinant role of 
the substrate access tunnel in the selectivity of ALDH1 towards bulky substrates 
such as retinal, whereas the bovine mitochondrial ALDH2 reveals a smaller and 
longer tunnel accessible to small substrates such as acetaldehyde[35]. The geometry 
of the catalytic tunnel is not the only mechanism exploited by ALDHs for 
substrates selectivity. Structural and biochemical studies on ALDH1A1 and 
ALDH1A2 suggested that the interaction of bulky substrates with a disorder loop 
(~ 457 - 477) located at the entrance of the substrate tunnel promotes a disorder to 
order transition[40], [41]. Activity assays, direct mutagenesis, Fluorescence 
Resonance Energy Transfer (FRET) analysis and structural studies on both 
hALDH1A1 and rat ALDH1A2 confirmed that the conformational adaptation of 
the disordered loop is a key step for the substrate recognition and catalysis[40], [41]. 




many aspects about substrate selectivity in ALDHs still need to been elucidated. 
Recently, MA Keller et al. (2014) published the structure of the fatty aldehyde 
dehydrogenase (FALDH). Their work identified a new mechanism in which 
FALDH uses a unique gatekeeper α-helix, at the entrance of the substrate tunnel, to 
regulate the access of the substrates[42]. 
Retinoid metabolism and retinoic acid signaling 
The etymology of retinol, retinal and retinoic acid derives from the term retina that 
refers to the organ where they were first identified[43]. Retinoids accomplish 
different roles in human metabolism. They are at the basis of the visual cycle, but 
at the meantime, they are crucial for embryonic development and tissues 
differentiation. The fat-soluble retinol, also known as vitamin-A, is up taken by 
dietary intake and it is the main source for retinoic acid (REA) biosynthesis. The 
conversion of retinol to all-trans retinoic acid goes through two reactions: the 
reversible conversion of retinol to all-trans retinal by alcohol dehydrogenase 
(ADH) or short-chain dehydrogenase (SDR), and the irreversible oxidation of all-
trans retinaldehyde to all-trans retinoic acid catalyzed by one of the three 
ALDH1A isoforms (Figure 7)[44]. The inactivation of retinoic acid is the last 
important step of the metabolism catalyzed by Cyp26 (also referred as P450RAI) 
that hydroxylate REA causing its inactivation[45]. Retinoids play an essential role in 
visual cycle that occurs in cone photoreceptor cell outer segments (OS) and in the 
retinal pigment epithelium (RPE). Photo isomerization of the 11-cis-retinal 
chromophore of rhodopsin triggers a complex set of metabolic transformations 



















Figure 7. Overview of metabolism and catabolism of retinoids with main enzymes involved in synthesis of 
retinoic acid and its inactivation[44]. 
 
The signaling role of retinoic acid have to be accomplished inside target cells, since 
that retinol is transported from plasma into target cells through the interaction 
between the retinol binding protein (RBP) and its receptor stimulated by retinoic 
acid 6 (STRA6)[47]. Inside the cells retinol can be segregated by cellular retinol 
binding protein (CRBP) or can be available as substrate for ADH and SDR and 
enter the retinoid metabolism (Figure 7)[48]. The final product of the retinoid 
metabolism is retinoic acid, a well-known signaling molecule with pleiotropic 
functions, fundamental for the spatial-temporal development of the embryo and the 
tissue development in adults[49]. The morphogen REA is essential in somitogenesis 
and axial elongation, cardiogenesis and neurogenesis. Therefore, unbalance in REA 
biosynthesis is cause of severe diseases at embryonic stage and in adult.  
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Using mice as flies is a mouse geneticist’s
dream. With an ever-increasing number of
mouse knockout strains available, the
dream is fast becoming a reality. We can
now carry out experiments to uncover
genetic interactions that until recently were
almost exclusively identified in inverte-
brates such as Drosophila melanogaster and
Caenorhabditis elegans. An example of such
an experiment is presented in the accompa-
nying paper1 by Karen Niederreither and
colleagues. These authors have identified
genetic interactions between two enzymes
involved in retinoid metabolism by crossing
mouse knockout strains carrying targeted
mutations in each. Their results deepen our
understanding of retinoid biology.
Retinoid metabolism
Retinoids are derived from dietary vita-
min A. Their main function is in cell sig-
naling, in which they bind two classes of
retinoid receptors, RARs and RXRs, that
belong to the family of nuclear hormone
receptors. These receptors are ligand-reg-
ulated transcription factors with essential
roles in embryonic development and
adult physiology. The biological impor-
tance of retinoids has long been known, as
major developmental abnormalities fol-
low retinoid deprivation or exposure to
excess retinoids. Some of these abnormal-
ities resemble congenital birth defects that
are relatively common in humans, includ-
ing spina bifida and cleft palate.
How are retinoids synthesized and
catabolized? Vitamin A (retinol) is con-
verted to retinaldehyde and then to all-
trans retinoic acid by way of two
oxidation steps (see figure). All-trans
retinoic acid is present in embryonic and
adult tissues at high levels, binds effi-
ciently to RARs, and is a major biologi-
cally active retinoid in vivo2. Some of the
remaining uncertainties stem from the
existence of additional retinoid metabo-
lites. For example, 4-hydroxy-retinoic
acid and 4-oxo-retinoic acid (see figure)
have been suggested to be inactive break-
down products of all-trans retinoic acid.
Other results, however, have raised the
possibility that these retinoids have
important biological functions3,4.
Although the picture remains incom-
plete, many of the critical enzymes involved
in retinoid metabolism have been identi-
fied. Oxidation of retinol to retinaldehyde
requires the activities of several alcohol
dehydrogenases (see figure)5. The second
step—oxidation of retinaldehyde to all-
trans retinoic acid—requires the action of
three related retinaldehyde dehydrogenases
and is generally believed to be the rate-lim-
iting step in the biosynthesis of all-trans
retinoic acid. This conclusion is supported
by several observations. For example, there
is a striking correlation between embryonic
expression of the aldehyde dehydrogenase
Retinoid metabolism: a balancing act
Thomas Perlmann
Ludwig Institute for Cancer Research, Karolinska Institute, S-171 77 Stockholm, Sweden. e-mail: thomas.perlmann@licr.ki.se
Published online: 15 April 2002, DOI: 10.1038/ng877
The recent characterization of the aldehyde dehydrogenase Aldh1a2 and the cytochrome P450 Cyp26, two enzymes involved in
retinoid metabolism, has helped to explain how bioactive retinoids are made and catabolized. By the elegant definition of an
Aldh1a2 null mutation as a dominant suppressor of a Cyp26 null mutation, it is now unequivocally demonstrated that the main



















Retinoid roundup. The biosynthetic pathway for generating all-trans retinoic acid involves two oxidation
steps, the first leading to the generation f all-trans retinaldehy e. The rate-limiting step in production of
all-trans retinoic acid in the embryo is mediated by three related aldehyde dehydrogenases, Aldh1a1,
Aldha2 and Aldha3. All-trans retinoic acid is converted to hydroxylated metabolites by Cyp26 (refs 7,8).
These hydroxylated derivatives are metabolized to other polar retinoid metabolites by additional enzy-
matic pathways. Niederreither et al.1 show that the impaired retinoid balance resulting from a Cyp26 null
mutation is rescued on an Aldh1a2 heterozygous background. This finding indicates that the main, if not































In late 1980s were identified for the first time the Retinoic acids Receptors (RARs) 
that are nuclear transcription factors inducible by retinoic acid binding[50], [51]. 
RARs are member of the nuclear hormone receptor superfamily and are composed 
by three subtypes RARα, RARβ and RARγ. RARs function as heterodimers with 
one member of the retinoid X receptors that are in turn composed by three subtypes 
RXRα, RXRβ and RXRγ. RAR-RXR heterodimers exert their pleiotropic effect of 
retinoic acid-dependent transcriptional regulators by binding to the specific 
Retinoic Acid Response Element (RARE) DNA sequences found in the promoter 
region of retinoid target genes[52]. The repression and activation of target response 
genes mechanism for RXR-RAR heterodimer is illustrated in Figure 8. The RXRs 
are able to bind 9-cis retinal and other ligands termed retinoxids, but 9-cis retinal 
cannot be detected endogenously in embryos or adult tissues. It is thus likely that 
RAR-RXR dimers act mainly, if not solely, by ligand binding of the RAR moiety, 
while RXR alone is not able to determine the activation of the target gene. This 
theory is supported by the fact that neither 9-cis retinal or other RXR ligands can 
rescue embryonic disease related to REA defeat[53]. Once identified the molecular 
basis of REA signaling, it is still tricky to elucidate all the mechanisms that are 
relevant to the REA mediated response. If on the one hand only about 20 genes 
have unambiguously RARE elements, on the other hand hundreds genes are 
involved in REA signaling or through direct interaction or through cross talk and 
signal cascades activation. Reflecting the complexity of REA response, the work of 
Liu et al. reported a total of 169 genes, including transcriptional factors, signal 
transduction modulators, protein modulators and cell cycle promoters and 
inhibitors, to be REA-modulated and form a harmonious network in the course of 























Figure 8. a) RXR-RAR heterodimers transcription factors bind to Retinoic Acid Response Element target 
genes. b) In absence of retinoic acid (REA) the system is repressed by transcriptional co-repressor (SMRT or 
NcoR) and by the histone deacetylase (HDACs). The binding of REA induces the release of the HDCA and the 
recruitment of Histone Acetyltransferase (HAT) co-activator complex that acetylates the histones for the de-
repression. Activation of the target gene is consequence of the transcription started by the RNA polymerase II 
holoenzyme, together with the TATA-binding protein (TBP), the TBP-associated factors (TAFs) and mediator 
complexes (MEDs). From Clarke et al.[55]. 
 
The embryonic development and cell fate determination of organisms are 
orchestrated by REA signaling, since that unbalance or absence of REA in embryos 
is cause of defects in the growth of central nervous system (CNS), craniofacial 
region, limb, urogenital system, lungs and heart. REA balance is determinant also 
in post-embryonic development and regeneration of lung, hair, ear and CNS[49]. 
Although is known that REA-activated pathway plays important, evolutionarily 
and conserved roles in neurogenesis, many of the detailed molecular interactions 





Retinoic acid was tested as therapeutic compound on brain cancer cell lines such as 
neuroblastoma and glioma. The thinking behind the use of retinoic acid against 
brain tumors is based on the observation that an undifferentiated cancer cell 
population is cause of a more aggressive cancer and poor prognosis. Since 
differentiation of cancer cells population is a goal in cancer treatment, the signaling 
role of REA in tissue differentiation should help to threat cancer. Even thought the 
ability of REA to differentiate neuroblastoma cell lines have been demonstrated, 
the clinical response to REA treatment is too variable[56]. REA-induced alterations, 
targeting undifferentiated glioblastoma cancer cells, lead to a differentiation of the 
cancer cells population, rendering them sensitive to targeted therapy. However 
retinoid signaling is even more complex in clinical gliomas, so that resistance and 
side effects were common[56], [57]. Hypotheses on inefficiency of REA treatment 
against brain tumors involves the possibility that REA is channeled to a pro-
proliferative, oncogenic pathway depending on the relative abundance of the 
REA[56]. 
 
ALDHs in Cancer Stem Cells (CSCs) 
First evidence of a cancer cell population with stem-like properties was reported by 
Bonnet and Dick in 1997 with their studies on acute myeloid leukemia[58]. In the 
early 2000s the Cancer Stem Cells (CSCs) theory was extended to breast cancer 
and glioma, two of the most studied tumors in relation to CSCs behavior[59], [60]. 
After almost 20 years of research, the scientific community agrees on the existence 
of a subpopulation of multipotent cancer cells with the ability to initiate the tumor. 
CSCs own the typical self-renewal/differentiation capacity of stem cells and it is 
quite likely that they are the engine of tumorigenisis in many cancers, not only in 
the formation of primary tumors but also for metastasis formation and reservoir of 
therapy resistant cells[61]. As clearly described by the work of Jordan et al., the 




which CSCs can be originated (Figure 9). The first scenario explains how the 
cancer stem cell that generates the primary tumor can derives from aberrant 
mutations of a normal stem cell or progenitor cell. The second scenario describes a 
situation in which refractory cancer stem cells, able to form a relapsed tumor, are 
consequence of chemotherapy treatment. The last scenario describes a tumor cell 










Figure 9. Three scenarios describing the origin of Cancer Stem Cells (CSCs) and their involvement in 
tumorigenesis, drug resistance and tumor propagation A) CSC generates from mutations to normal stem cell or 
progenitor cell. The generated CSC gave rise to the primary tumor. B) Chemotherapy treatment of the primary 
tumor cause a refractory cancer stem cell able to generates a relapsed tumor. C) A tumor cell escape from the 
primary cancer generates a metastatic cancer stem cell that originates metastasis[61]. 
 
Although the existence of a CSCs subpopulation has been proof and accepted, their 
identification is still controversial. Over the recognition through associated 
markers, CSC detection needs to be confirmed through a “gold standard” test that 
consists in the validation of CSCs ability to start a new tumor ex vivo or after 
xenotransplantation in animal models[60]. Up to date the relation between specific 
cancer markers and CSCs presence is still argument of debate. In Table 2 are listed 
the majority of the markers that have been somehow correlated to CSCs. Diverse 
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Unique molecular features of leukemia stem 
cells may provide opportunities for therapeutic 
intervention. For example, there is evidence of 
constitutive activation of both the nuclear factor-
κB (NF-κB) and phosphatidylinositol 3′ (PI3) ki-
nase signaling pathways in AML stem cells.28,44 
Neither NF-κB nor PI3 kinase activity is detect-
able in resting, normal hemat poietic stem cells, 
so both of these molecular factors could be tumor-
specific targets. Two studies with different meth-
ods of pharmacological inhibition of NF-κB have 
reported specific eradication of AML stem cells 
in vitro, without apparent harm to normal hema-
topoietic stem cells.45,46 A separate study demon-
strated that inhibition of PI3 kinase reduced the 
growth of AML stem cells.44 Similarly, inhibition 
of the dow stream PI3-kinase mammalian target 
of rapamycin (mTOR) appears to enhance the 
activity of the chemotherapeutic agent etoposide 
against AML stem cells.47 Inhibition of mTOR 
also blocks the growth of leukemia-initiating 
cells in a mouse model of AML.48 Taken together, 
these findings indicate that leukemia stem-cell–
specific therapies may be attainable.
Cancer Stem Cells in the Central Nervous 
System
Isolation of cancer stem cells of the central ner-
vous system (CNS) has been achieved by means 
of antigenic markers and by exploiting in vitro 
culture conditions developed for normal neural 
stem cells. As was first observed in 1992,49,50 CNS 
cells grown on nonadherent surfaces give rise to 
balls of cells (neurospheres) that have the capac-
ity for self-renewal and can generate all of the 
principal cell types of the brain (i.e., neurons,
astrocytes, and oligodendrocytes). Neurospheres 





















Figure 3. Scenarios Involving Cancer Stem Cells.
For tumors in which cancer stem cells play a role, at least three scenarios are possible. First, mutation of a normal 
stem cell or progenitor cell may create a cancer stem cell, which will then generate a primary tumor (Panel A). Sec-
ond, during treatment with che otherapy, the majority of cells in a primary tumor may be destroyed, but if the can-
cer stem cells are not eradicated, the tumor may regrow and cause a relapse (Panel B). Third, cancer stem cells aris-
ing from a primary tumor may emigrate to distal sites and create metastatic lesions (Panel C).
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 




markers were scrutinized only for cell lines and does not have evidence in other 
cancer cell lines or in vivo[62]. The discovery of more specific and reliable markers 
among with the development of standard protocol for the evaluation of CSCs 
presence is a desirable goal for cancer research. 
Table 2. List of molecular markers for CSC adapted from[62]. This list is not exhaustive and includes markers 
not exhaustively tested. 





































































 ALDHs as cancer stem cell markers 
ALDHs are good candidates for the identification of CSCs and has been used as 
marker for many solid tumors including breast, brain, lung, liver, colon, pancreatic, 
ovarian, head and neck, prostate and melanoma[5]. ALDHs are a multipurpose tool 
in CSCs studies because they couple the detection of the CSC subpopulation with 
the selection of ALDH-positive cells through Fluorescence Activated Cell Sorting 
(FACS) with ALDEFLUOR™ assay. This technique is suitable for FACS that uses 
BODIPY aminoacetaldehyde (BAAA) as modified fluorescent substrate for 
ALDH. Cells with high ALDH activity convert BAAA in the cytoplasm into the 
negatively charged BODIPY aminoacetate (BAA-), which is retained into the cells 
that appear as a distinct cohort of cells exhibiting green fluorescence[63]. High 
aldehyde dehydrogenase activity in breast, myeloid leukemia, prostate, rectal, 
oesophageal, lung, ovarian and gallbladder cancers is predictive of worst outcome, 
therefore ALDHs are being scrutiny as a potential prognostic markers[64]. The 
identification and correlation of specific ALDH isoforms to the presence of CSC 
subpopulation and a poor cancer prognosis has been reviewed from Marcato et al. 
[65] and Pors et al.[66] (Table 3). Initially most of the studies reported ALDH1A1 as 
the signature marker for CSCs in many cancers, but its correlation with CSCs was 
overestimated because ALDEFLUOR™ does not specifically detect only 
ALDH1A1 activity. The capability of ALDH to process different aldehydes doesn’t 
guarantee the isoform specificity for the ALDEFLUOR™, therefore detection of 
specific isoforms in CSC is under review and it need to be supported with different 









Table 3. List of ALDH isoforms detected in various cancers and their correlation with cancer prognosis. 
Adapted from Rodriguez-Torres et al.[64]. IHC is immunohistochemistry, HNSCC is Head and Neck Squamous 
cell carcinoma. 
Tumor Type Method of ALDH 
detection 
ALDH isoform Clinical observation 





Poor clinical outcome, tumor 
recurrence, poor response to 
chemoterapy 




Poor clinical outcome 
Brain cancer ALDEFLUOR, IHC, 





Bone cancer ALDEFLUOR ALDH Poor clinical outcome 
Prostate Cancer ALDEFLUOR, IHC ALDH7A1 
ALDH3A1 
Poor clinical outcome 
HNSCC ALDEFLUOR, IHC ALDH1A1 Poor clinical outcome 
Colorectal cancer ALDEFLUOR, IHC ALDH1 
ALDH1A1 
Loss of ALDH expression  




ALDH1A1 poor clinical 
outcome, recurrence 






Endometrial cancer ALDEFLUOR, IHC ALDH1 
ALDH1A1 
Not assessed 
Renal cancer IHC, Immunoblotting ALDH1 
ALDH1A1 
Poor clinical outcome 





Heptobiliary cancer ALDEFLUOR, IHC ALDH1A3 
ALDH3A1 
Poor clinical outcome 
Oesophageal cancer ALDEFLUOR, IHC ALDH1 
ALDH1A1 







Focusing on specific ALDH isoforms that concerned cancer research, ALDH1A3 is 
gaining more importance in CSC biology and detection. Marcato et al. in 2011 
found that the overexpression of ALDH1A3, and not ALDH1A1 was predictive of 
metastasis in breast cancer stem cells[67]. In 2014 Shao et al. demonstrated the 
importance of ALDH1A3 for the maintenance of non-small lung cancer stem 
cells[68], whereas Mao et al. in 2013 found overexpression of ALDH1A3 in 
glioblastoma stem cells[69]. 
ALDH1A3 in glioma 
The World Health Organization (WHO) classified gliomas in four histological 
grades by increasing degrees of undifferentiation, anaplasia, and aggressiveness[70]. 
Glioblastoma or High Grade Gliomas (HGGs) are classified as WHO grade III and 
IV and account 82% of gliomas[71]. Glioblastoma are highly invasive, infiltrative 
and recurrent brain tumors with a 5 years survival < 5%[71], [72]. The presence of a 
cancer stem cell population in glioma and in its more aggressive declinations has 
been proof, thereafter glioma stem cells (GSCs) are on the apex in a cellular 
tumorigenic hierarchy of HGGs[73], [74]. Microarray gene expression data, 
immunohistochemistry and biomarkers studies propose the existence of two glioma 
stem cell populations: the proneural glioma stem cells (PN GSCs) and the 
mesenchymal glioma stem cells (Mes GSCs)[69]. In the mesenchymal phenotype of 
HGG it has been demonstrated that the concurrent activation of two conflicting 
transcriptional regulators for neurogenesis and gliogenesis operates to permanently 
drive the aberrant mesenchymal phenotype in the context of the genetic and 
epigenetic changes that accompany high-grade gliomagenesis[75]. 
Mao et al. found high expression of ALDH1A3 isoform in GSCs. The expression 
of hALDH1A3 was detected by whole transcriptome microarray analysis and was 
found to be about 1000 times more in Mes GSCs compared to other cancer stem 
cells subpopulation (Figure 10). In vivo studies and xenograft experiments 













Figure 10. ALDH1A3 is a functional Mes GSC marker. (A) qRT-PCR analysis of ALDH1A3 expression in PN 
and Mes GSCs (**P < 0.01). (B) FACS analysis using Aldeflour™. ALDH activities in PN GSCs (n = 3), Mes 
GSCs (n = 3), and non-GSCs (n = 3) derived from Mes GSCs (**P < 0.01)[69]. 
 
The high activity (detected by ALDEFLUOR™) and the overexpression (detected 
by mRNA microarray) of ALDH1A3 in Mes GSCs are related with the high 
tumorigenicity, aggressiveness and worst prognosis of Mes GSC derived HGG. 
This research work lays the foundation for the validation of ALDH1A3 protein as 
interesting target in glioma.  
ALDHs and cancer stem cell therapy resistance 
Chemotherapy and radio resistance in tumors are the major difficulties that cancer 
research is facing and represent one of the most challenging barrier in cancer 
treatment. The resistance to treatments can be inherent or acquired by cancer cells, 
and mechanism such as DNA repair, drug efflux, drug inactivation and other 
















Figure 11. Overview on cancer drug resistance. Pharmacokinetics (PK) and Pharmodynamics (PD) are the two 
critical mechanisms where the drug can be limited on its effect in cancer treatment by drug resistance 
mechanism of the cell or absorption, distribution, metabolism and elimination factors. From Holohan et al.[76]. 
 
The plethora of mechanisms that tumor cells use to contrast cancer treatments 
includes CSCs that are often mentioned as one of the main actors in therapy 
resistance. Radio and chemo resistance of CSCs are in turn a consequence of a 
multiplicity of defense mechanisms such as DNA damage response, ABC 
transporters, slow cycling rate and high ALDH expression[12]. First evidence of 
cytotoxic drug resistance, due to ALDH high activity, was observed for 
cyclophosphamide treatment[12], in which ALDH1A1 has been observed to oxidize 
pivotal aldehyde intermediates of pro-drug cyclophosphamide and its analogues[77]. 
Other drugs such as doxorubicin, paclitaxel and A459-Taxol used in breast and 
lung cancer chemotherapy might be associated with high ALDH expression. It is 
still to be understood case by case if ALDHs are the cause of drug resistance or 
biomarkers of cancer cells that gain drug resistance[12]. The different situations in 
which ALDHs are involved in CSC biology can lead to different strategies: the 
development of selective inhibitors or the use of ALDH isoforms as biomarker and 




in complex with its ligand and the structured-based design of small molecules are 
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Outline of the thesis 
Aldehyde dehydrogenases (ALDHs) are detoxifying enzymes that uses NAD(P) as 
cofactor to oxidizes aldehydes into their corresponding carboxylic acids. The 
human ALDH superfamily consist of 19 isoforms classified in families and 
subfamilies by sequence identity. Human ALDHs comprise crucial enzymes 
involved in many metabolic and signaling processes such as the retinoid 
metabolism, the neurotransmitter (GABA) biosynthesis and osmosis (betaine) 
regulation. 
ALDH1A1, ALDH1A2 and ALDH1A3 are the three cytosolic isoenzymes 
composing the ALDH1A subfamily. They are key regulators of the biosynthesis of 
retinoic acid (REA) that is an important signaling molecule at the basis of the 
embryonic development and tissue differentiation. ALDH1A1 and ALDH1A3 are 
the two isoforms that are gaining importance in cancer studies for their role in 
Cancer Stem Cells (CSCs) biology. CSCs are a reservoir of tumorigenic cells with 
self-renewal/differentiation capacity, high tolerance to radio and chemotherapy and 
with the ability to initiate and propagate tumors. The intrinsic CSCs high-ALDH 
activity is exploited for their identification and selection through ALDEFLUOR™. 
In summary, the high expression of ALDH isozymes in each cancer type is likely 
correlated to CSCs presence, worst outcome of the tumor and drug resistance. 
Focusing on ALDH1A3, its high expression and activity has been detected in 
mesenchymal Glioma Stem Cells (Mes GSCs) of High Grade Gliomas (HGGs) that 
are the most aggressive brain cancers, affecting people of all ages. The primary 
treatment for glioma is the surgical removal however, because it is an invasive and 
aggressive cancer, the neurosurgery can’t remove the entire tumor mass and 
doesn’t avoid the return of the glioma. The high invasive nature of HGG and its 
recurrence have been associated with the presence of Glioma Stem Cells (GSCs), 
in which ALDH1A3 seems to play a critical role.  
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In the present Ph.D. dissertation, we provide the biochemical characterization and 
the X-ray crystal structure of hALDH1A3 in complex with its ligands. Steady state 
kinetic constants for hALDH1A3 showed Michaelis-Menten kinetics and 
confirmed the preference of the enzyme for its natural substrate all-trans retinal. 
Moreover the interaction of the enzyme with its ligands was investigated by 
Thermofluor assay. Thermal shift data underline a high affinity of ALDH1A3 for 
the oxidized cofactor and evidence a certain grade of affinity also for the products 
of the reaction. The structure of ALDH1A3 in complex with the cofactor and the 
natural product was solved by means of X-ray crystallography at a resolution up to 
2.9 Å. The ALDH1A3 crystal asymmetric unit comprises 8 polypeptides arranged 
in two distinct catalytic tetramers. Each ALDH1A3 monomer binds one molecule 
of NAD+, and in addition electron density corresponding to product REA was 
found in complex with four chains. 
Structural investigations on hALDH1A3, together with its biochemical 
characterization, are useful tools to help unravel the role of this enzyme in GSCs 
biology. The reported structure, notably in complex with REA and NAD, was the 
necessary preliminary data for the first in silico screening of commercially 
available compounds with potential activity as inhibitors. Studies on inhibition and 
selectivity of compound hits resulting from the virtual screening are on the way. 
The structure-based design of small ligands is a critical step for the identification of 
a lead compound or for the modeling of an isoform specific fluorescent probe for 
prognosis and diagnostic purposes. 
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ABSTRACT 
The aldehyde dehydrogenase family 1 member A3 (ALDH1A3, E.C. 1.2.1.5) 
catalyzes the oxidation of all-trans retinal to retinoic acid (REA) using NAD+ as 
cofactor. The human ALDH1A3 plays a key role in embryonic development and 
tissue differentiation by regulating the synthesis of the pleiotropic retinoic acid. 
ALDHs high enzymatic activity is a marker of Cancer Stem Cells (CSCs) 
population in some tumors and it seems to be related to cell proliferation, survival 
and chemoresistance of CSCs. The detection of ALDH1A3 high expression in 
mesenchymal Glioma Stem Cells (Mes GSCs), with respect to ALDH1A1 and 
ALDH1A2 isoforms, addresses potential medical interest on the isoenzyme as 
prognosis marker or inhibitors target.  
Here we present the first X-ray structure of human recombinant ALDH1A3 co-
crystallized with NAD and REA. The structure model reveals a new conformation 
of NAD+ and two different conformations of REA in complex with the enzyme. In 
addition our work contributes to complete the functional characterization of 
ALDH1A3 by reporting steady state kinetic constants and melting temperatures 
(Tm) of the enzyme with its ligands, measured by continuous spectrophotometric 
assay and thermofluor experiments, respectively. In summary, our data provide a 
first comprehensive structural view of ALDH1A3 combined with its biochemical 
characterization. These results can be a valuable tool for structure-based drug 
design of ALDH1A3 potential inhibitors and for the detection of ALDH1A3 
isoform in glioma as prognosis marker.  
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INTRODUCTION 
Living organisms are constantly confronted with oxidative stress and with the 
reactive oxygen species (ROS) derived therefrom. In animals a plethora of 
mechanisms contribute to ROS formation and the superfamily of Aldehyde 
dehydrogenase enzymes (ALDHs) are known to decrease oxidative stress, 
particularly that caused by aldehydes. During numerous physiological processes, 
aldehydes are generated from a variety of precursors, including the endogenous 
biotransformation of most compounds such as amino acids, neurotransmitters, 
carbohydrates and lipids[1], [2]. Aldehydes are ubiquitous molecules present in the 
environment from natural sources and from pollution and cigarette smoke. 
Moreover, they are approved additives in various foods and are also used or 
generated in a wide variety of industrial processes. As some aldehydes play vital 
roles in normal physiological processes like vision, embryonic development, and 
neurotransmission, many are cytotoxic and carcinogenic[3]. ALDHs enzymes are 
required for the clearance of potentially toxic aldehydes, and are essential for the 
production of key metabolic regulators[2]. Most of the ALDHs have wide tissue 
distribution displaying distinct substrate specificities[2], [4]. The human ALDH 
superfamily consists of 19 putatively functional genes with different chromosomal 
locations[5]. A standardized gene nomenclature system based on divergent 
evolution and amino acid identity was established for the ALDH superfamily in 
1998[6]. The ALDH enzymes catalyze the NAD(P)+-dependent irreversible 
oxidation of a wide spectrum of endogenous and exogenous aldehydes and are 
found in all subcellular regions including cytosol, mitochondria, endoplasmic 
reticulum and nucleus, with several of those found in more than one 
compartment[7]. 
In particular, ALDH1A1, ALDH1A2, ALDH1A3, which are the three members of 
the cytosolic aldehyde dehydrogenase class 1 of higher vertebrates, have a key role 
in vertebrate development. Indeed, they show a high specificity for retinaldehyde, 
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oxidizing it to the powerful differentiation factor retinoic acid (REA)[8]. The 
retinoic-acid signaling pathway in vertebrates utilizes two classes of retinoid 
receptors, RARs and RXRs that belong to the family of nuclear hormone receptors. 
These proteins are ligand-regulated transcription factors that bind 9-cis (RXR, 
RAR) or all-trans (RAR) retinoic acid via a ligand-binding domain, and direct the 
transcription of target genes via a DNA-binding domain[9], [10]. Retinoic acid is 
derived from vitamin A (retinol) and its pleiotropic effects include spinal chord and 
retina development during embryogenesis, neuronal cell differentiation and 
maintenance of epithelial cell type in adult tissues[11]. Synthesis of REA proceeds 
through two steps: the oxidation of retinol by alcohol dehydrogenase producing the 
relative aldehyde, followed by its irreversible conversion to acid using retinal 
dehydrogenases[12]. The ALDH1A3 sequences shares more than 70% amino acid 
conservation with ALDH1A1 and ALDH1A2 and major amino acid residues found 
in the catalytically active sites of ALDHs are conserved. Despite processing the 
same substrate the expression of ALDH1A1, 1A2 and 1A3 are not entirely 
redundant considering their preference for specific substrates.  
Indeed, ALDH1A1 shows substrate preferences for the aldehydes products of lipid 
peroxidation as well as retinaldehyde. Otherwise ALDH1A2 and ALDH1A3 
exhibit the highest substrate specificity and catalytic efficiency for retinal oxidation 
to REA[13]. In addition, ALDH1A3, although capable to catalyzes the oxidation of 
cis-retinal to REA, displays a strong specificity for all-trans retinal with an 
efficiency that is 10-fold higher than that of ALDH1A1 and ALDH1A2[14]. In 
summary, the most efficient retinal dehydrogenase activity was reported for the 
cytosolic enzyme ALDH1A3 that oxidizes both all-trans-retinal and 9-cis-retinal to 
REA[14]. Moreover, such high specificity of ALDH1A3 for all-trans-retinal 
indicates the requirement of restricted all-trans configuration of the carbon side 
chain in the retinal substrate characterizing this isoenzyme with respect to the other 
two. The ALDH1A3 is differentially activated during early embryonic head and 
forebrain development, and it is expressed at high levels in the differentiating 
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keratinocytes of human and murine hair shafts. Otherwise a low to negative 
expression level of ALDH1A3 was reported for the interfollicular epidermis[15], [16]. 
Moreover, knockout of the murine ALDH1A3 gene was associated with perinatal 
lethality that could be rescued by maternal treatment with REA[17].  
The milieu of cancerous tumors consists of heterogeneous cell population and 
increasing evidence indicates Cancer Stem Cells (CSCs) as the self-renewal and 
differentiation population of cells able to driving tumorigenesis[18]. In this contest, 
high aldehyde dehydrogenases activity is being scrutiny as a potential prognostic 
marker for cancer. Indeed, the ALDHs enzymatic activity was found modified in 
CSCs population and seems to be correlate with a poor outcome for many solid 
tumors[19]. Recently, ALDH1A1 was found to be expressed in AldefluorTM-positive 
CSCs from human melanoma and breast cancer. As such, it is unlikely that the 
ALDH enzymatic activity measured by AldefluorTM is due only to ALDH1A1. 
Recent studies found that tumor aggressiveness and metastasis in human breast 
cancer were correlated with ALDH1A1 instead of ALDH1A3[20], [21]. This finding 
underscores the importance of defining the ALDH isoenzymes responsible for the 
high ALDHs activity in each cancer type and provides compelling evidence in 
favor of the ALDH isoenzymes functioning as key molecules governing cell 
proliferation, survival and chemoresistance of CSCs[22]. Given the accumulating 
and evolving evidence of ALDH role in CSC biology, the selective suppression of 
ALDH isozymes and genes may be a promising frontier for CSC-directed 
therapeutics in human cancers. It is hoped that this may spur the development of 
novel and highly specific inhibitors[23], [24].  
In this contest, recently, it has been demonstrated the elevated expression of human 
ALDH1A3 in mesenchymal Glioma Stems Cells (Mes GSCs) with respect to 
human ALDH1A1 and all other ALDHs. Mao et al. investigate GSCs by 
transcriptome array analysis and found high expression of hALDH1A3 isoform in 
High Grade Gliomas (HGGs) generated form Mes GSCs[25]. The hALDH1A3 is 
highly expressed in clinical HGGs but not in low-grade glioma (LGGs) and in 
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normal brain samples. In particular, it is possible to classify two distinct 
populations of GSCs in HGGs: the proneuronal glioma stem cells (PN GSCs) and 
mesenchymal glioma stem cells (Mes GSC). The HGG derived from Mes GSCs in 
which hALDH1A3 is significantly up regulated displays a higher radioresistance 
and aggressiveness compared to HGG derived from PN GSCs. In addition, 
irradiation induces hALDH1A3 up-regulation in treated cancer cells transforming 
PN GSCs derived gliomas into tumor cells that are highly resistant to radiation 
treatment[24]. Taken together, this data suggest that subtypes of GSCs in clinical 
HGG tumor tissues are identifiable by up-regulation of ALDH1A3 activity that 
distinguishes Mes GSCs from PN GSCs[25].  
Here we report on the first crystal structure of the human ALDH1A3 enzyme in 
complex with REA and NAD+, which has been determined at a 2.9 Å resolution. 
Such structural analysis is the instrument in order to better understand the 
differences in substrate specificity between ALDH1A subfamily enzymes, and 
complete the overall view of the catalytic and metabolic function of this important 
family of enzymes. The structural determination of ALDH1A3 in complex with its 
ligands is the critical issue to start planning a structure based design of potential 
inhibitors with medical interest and to generate fluorescent probes that should be 
useful for early diagnosis in glioma and other tumors expressing ALDH1A3.  
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EXPERIMENTAL PROCEDURES 
Expression and purification of human ALDH1A3 
The human ALDH1A3 gene was amplified by PCR from mesenchymal Glioma 
Stem Cell cDNA pool with the synthetic oligonucleotides primers 5’-
CACCGCCACCGCTAACGGGGCCGTG-3’ and 5’-
TCAGGGGTTCTTGTCGCCAAGTTTGATGGTGACAGT-3’. The full-length 
hALDH1A3 was cloned into the destination vector pDEST17 that provides an N-
term 6xHis tag and transformed in. E. coli strain BL21(DE3) (Novagen). The next 
day, colonies were scraped and inoculated in one liter 2xTY medium supplemented 
with 50 µg/mL ampicillin. When OD600 of 0.6–0.8 was reached, the temperature 
was shifted to 20°C to induce the recombinant protein production. Induced cells 
collected by centrifugation, were resuspended in 1/25 original volume of lysis 
buffer (50 mM Na2HPO4, 300 mM NaCl, 1mM β-mercaptoethanol, 10 mM 
imidazole at pH 7.5) supplemented with 250U of Benzonase nuclease. Afterwards, 
bacterial cells were fragmented by applying a high pressure through the use of the 
French Press. Protease inhibitor cocktail was added to the crude extract and the 
lysate was clarified with centrifugation at 39,000 rcf. To evaluate the purity and 
homogeneity of the protein, after each purification step, eluted fractions were 
analyzed by SDS-PAGE and the protein quantification was determined by 
Bradford protein assay. In the first purification step, the soluble fraction of 
recombinant human 6xHis-ALDH1A3 was purified with a Qiagen Ni-NTA 
Superflow 5 mL cartridge. The supernatant was loaded on the Ni-NTA column, 
previously equilibrated with 10 column volumes of lysis buffer. The Ni-NTA 
cartridge was washed with 50 mM Na2HPO4, 300 mM NaCl, 1mM β-
mercaptoethanol, 50 mM imidazole pH 7.5 until the absorbance (A) at 280 nm 
return to the baseline (15 column volumes). The recombinant protein was eluted by 
a linear gradient in 20 column volumes with the buffer as follow: 50 mM 
Na2HPO4, 300 mM NaCl, 1mM β-mercaptoethanol, 250 mM imidazole pH 8. 
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Eluted fractions were pooled and concentrated to 5 mg/ml with Merck Millipore 
Amicon Ultra-15 10 kDa and loaded on a Sephacryl S200 16/60 column on AKTA 
FPLC system. The protein was eluted and stored in buffer containing 20 mM 
HEPES pH 7.5, 150 mM KCl, 1mM β-mercaptoethanol, 0.5 mM EDTA. This 
procedure allowed us to obtain from one liter of bacterial culture 25 mg of pure and 
active hALDH1A3 used for crystallization trials and kinetics analysis. 
Enzyme kinetic analysis and thermal shift assay 
The hALDH1A3 activity was followed by continuously measuring the NADH 
formation at 340 nm (molar extinction coefficient of 6220 M−1 cm−1) for 30 
minutes at 25°C with Varian Cary® 50 UV-Vis spectrophotometer. The enzymatic 
assays were performed in a total volume of 200 µl in 20 mM Tris HCl pH 8.0, 1 
mM β-mercaptoethanol, 150 mM KCl, with 2.6 µM of pure recombinant 
ALDH1A3. The biochemical characterization of the enzyme was performed by 
measuring the enzymatic steady state kinetics at variable concentrations of all-trans 
retinal (from 0.02 µM to 60 µM), acetaldehyde (from 0.05 mM to 20 mM) and 
NAD from 0.2 µM to 10 mM. Michaelis-Menten kinetics[26] analysis of three 
independent experiments was performed using SigmaPlot (Systat Software, San 
Jose, CA). All the compounds were purchased from Sigma Aldrich and were 
dissolved in water except all-trans retinal that was dissolved in DMSO. Each assay 
was pre-incubated without enzyme for one minute, than the ALDH1A3 was added 
to initiate the reaction.  
For the thermofluor assay, ALDH1A3 was diluted to a final concentration of 1 
mg/mL using 20 mM HEPES pH = 7.5, 150 mM KCl, 1 mM β-mercaptoethanol, 
0.5 mM EDTA as the buffer solution. The thermal shift assay was performed using 
a MiniOpticon™ Real-Time PCR Detection System (Bio-Rad) with FAM emission 
wavelength. The melting temperature (Tm) were recorded in triplicates and 
calculated as described by Matulis et al.[27]. The Tm was calculated as the inflection 
point of the sigmoidal melt curve and increased Tm indicates increased global 
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stability. For the thermal shift analysis, ALDH1A3 was mixed with an appropriate 
amount of stock solutions of NAD+, NADH, all-trans retinal and retinoic acid to a 
final concentration of 1 mM and with the fluorescence probe SYPRO® Orange 
(Sigma–Aldrich) at 1/4000 dilution. Data were harvested and analyzed using CFX 
Manager™ Software (Bio-Rad) and SigmaPlot. 
Crystallization and Structure Determination  
Crystals of hALDH1A3 were obtained by using the vapor-diffusion technique in a 
sitting drop and applying a spare-matrix-based strategy on a crystallization robot 
(Oryx4, Douglas Instruments) with commercially available crystallization kits 
(Qiagen, Hamapton). Best crystals grown by mixing 0.5 µl of protein solution at 
5.5 mg/mL, pre-incubated with 1 mM NAD and 1 mM retinoic acid, with an equal 
volume of a reservoir solution containing 20% PEG 3350, 0.24 M Na2 malonate pH 
7.0, 10 mM TCEP hydrochloride and equilibrated against 50 µl of the reservoir 
solution, at 20 °C in about 30 days. For X-ray data collection, crystals were quickly 
equilibrated in a solution containing the crystallization buffer and 12.5% glycerol 
as cryo-protectant and flash frozen at 100 K in liquid nitrogen. A complete dataset 
for human ALDH1A3 was collected up to 2.9Å resolution at the ID23 EH1 
beamline of the European Synchrotron Radiation Facility (ESRF, Grenoble, 
France). Analysis of the diffraction data set, allowed us to assign the crystal to the 
monoclinic P 1 21 1 space group with cell dimensions a = 82.66 Å b = 159.79 Å 
and c = 155.65 Å, containing eight molecules per asymmetric unit with a 
corresponding solvent content of 55.5%. Diffraction data were integrated using the 
program package XDS[28] and scaled with the CCP4 suite of program[29]. The 
structure determination of hALDH1A3 was carried out by means of the molecular 
replacement technique using the coordinates of Ovis aries ALDH1 tetramer as the 
search model (Protein Data Bank ID code 1BXS). The program PHASER[30] was 
used to automatically determine the hALDH1A3 structure and returned a unique 
molecular replacement solution with an LLG of 4716.971 and TFZ=11.3. The 
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resulting electron density map of human ALDH1A3 allowed automatic tracing by 
the program AUTOBUILDING[31]. The initial model was subjected to iterative 
cycles of crystallographic refinement with the programs REFMAC5[32] and 
PHENIX.REFINE[33] alternated with manual graphic session for model building 
using the program Coot[34]. 5% randomly chosen reflections were excluded from 
refinement of the structure and used for the Free R factor calculation[35]. The 
program ARP/wARP[36] was used for adding solvent molecules. Refinement was 
continued until convergence to R factor and Free R factor to 0.224 and 0.286 
respectively and ideal geometry. Data collection and refinement statistics are given 
in Table 1. The stereochemistry of the model has been assessed with the program 
PROCHECK[37]. Consensus amino acids sequence for ALDH1A3 start at 1 
resulting in a shift of +12 compared to the reference sequence of mature ALDH2 
Illustrations  
Figures were generated by using the program pymol[38] and LigPlot+[39].  
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Table 1. Data collection and refinement statistics for hALDH1A3 crystal. 
 
 hALDH1A3 crystal 
DATA COLLECTION   
Space group  P 1 21 1 
Cell dimensions   
       a, b, c (Å)  82.66, 159.79, 177.65 
       α,β,γ (°)  90, 93.69, 90 
Resolution (Å)  47.51 - 2.9 
Rpim /  Rmerge  0.109(0.490)/0.184(0.785) 
Mean(I) / sd(I)  5.4 (1.6) 
Completeness (%)  98.3 (97.3) 
Redundancy  3.6 (3.2) 
  
REFINEMENT  
Resolution (Å)  2.9 
No. reflections  100139 (9865) 
Rwork / Rfree 0.2244 / 0.2869 
No. atoms   
       Protein  29498 
       Water  66 
       Ligands 462 
Mean B-factors   
       Protein (Å2) 40.5 
       Water (Å2) 13.8 
       Ligands (Å2) 45.8 
R.m.s deviations   
  Bond lengths (Å)  0.017 
  Bond angles (°)  1.74 
Ramachandran outliers (%) 0.63 
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RESULTS AND DISCUSSION 
Biochemical characterization 
The kinetic characterization of hALDH1A3 was performed in presence of NAD+ 
varying the concentration of the natural substrate all-trans retinal and acetaldehyde, 
a substrate accepted among different ALDH isoforms[40]. Plots of initial velocity 
versus either substrates or NAD+ concentrations showed Michaelis–Menten 
kinetics, summarized in Table 2.  
Table 2. The biochemical characterization of hALDH1A3. The steady state kinetics were measured varying 
the concentration of NAD+, the natural substrate all-trans retinal and acetaldehyde. 
Variable Substrate Fixed Substrate Km Kcat Kcat/Km 
Acetaldehyde NAD+ 2.4x10-3 M 0.1 s-1 4.1x101 M-1s-1 
NAD+  Acetaldehyde 77.5x10-6 M 0.1 s-1 1.3x103 M-1s-1 
All-trans retinal NAD+ 9.3x10-6 M 1.6 s-1 1.7x105 M-1s-1  
NAD+   All-trans retinal 4.8x10-6 M 2.0 s-1 4.2x105 M-1s-1 
The steady state kinetic data are consistent with others ALDH1s described in 
literature[40], [41]. Indeed, the decrease in the Km values of 258-fold for all-trans 
retinal than acetaldehyde, confirms the substrate specificity of this human 
isoenzyme. Moreover, the measured Km for NAD+ is almost 2 times lower than the 
Km for retinal and it is comparable to the constant measured for others ALDHs[42]. 
Noteworthy, turnover number for all-trans retinal oxidation (kcat=1.6 s-1) is ~12 
times higher compared to ALDH1A2 and ~18 times higher than ALDH1A1[43] and 
it confirms the preference of ALDH1A3 for all-trans retinal whit respect to 1A1 
and 1A2.  
The global stability of hALDH1A3 in complex with the oxidized and reduced 
cofactor and with all-trans retinal and retinoic acid (REA) was investigated for the 
first time by Thermofluor assay, as described in materials and methods [27], [44]. The 
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melting temperature (Tm) of hALDH1A3, calculated in absence or presence of 
ligands, showed a highly significant thermal shift for this enzyme coupled with the 
oxidized form of the cofactor (Figure 1).  
 
 
Figure 1. Thermal shift of hALDH1A3 in complex with its ligands. A) Tm of the apoALDH1A3 (orange) 
compared with the enzyme in complex with NAD+ (blue) and NADH (green) B) Tm of the apoenzyme 
(orange) compared with the melting temperatures of the ALDH1A3 in complex with the substrate retinal (grey) 
and the product retinoic acid (light orange) C) Tm of the apoALDH1A3 (orange) compared with the enzyme in 
complex with NAD+ and retinal (light green) and NAD and retinoic acid (light blue). D) Table of Tm of 
ALDH1A3 in complex with its ligands. Measured Tm for ALDH1A3 alone or in complex with oxidized and 
reduced cofactor and with all-trans retinal substrate and retinoic acid product. The ΔTm is expressed as 
difference between the Tm of ALDH1A3 in complex with ligands and the Tm of the apoenzyme.  
The binds of NAD+ increased the global stability of the enzymes (ΔTm 8.3 °C) 
compared to the reduced form of the cofactor (ΔTm 2.3 °C). Noteworthy was 
possible to identify a significant interaction of the protein with the product retinoic 
acid (ΔTm 2.5 °C), whit respect to the substrate all-trans retinal (ΔTm < 2 °C, 



















































Protein Ligand Tm ±  SD ΔTm 
ALDH1A3  57.5 °C ± 0.05  
ALDH1A3 NAD+ 65.8 °C ± 0.04 8.3 °C 
ALDH1A3 NADH 59.8 °C ± 0.07 2.3 °C 
ALDH1A3 All-trans retinal 58.3 °C ± 0.04 0.8 °C 
ALDH1A3 Retinoic acid 60.0°C ± 0.01 2.5 °C 
ALDH1A3 NAD+ and all-trans retinal 63 °C ± 0.06 5.5 °C 
ALDH1A3 NAD+ and retinoic acid 64.5°C ± 0.1 7 °C 
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capability to stabilize the complex compared to any other tested ligands. 
Furthermore, the measured Tm evidences a certain grade of affinity also for the 
products of the reaction. The NAD+ influence on the stability of the enzyme was 
also tested in presence of both the substrate and product. As expected, the Tm for 
ALDH1A3 incubated with NAD+/retinal and NAD+/retinoic acid is, for both, lower 
than NAD+ alone but higher respect to the single substrate or product. 
Overall Quality of the model 
The three-dimensional structure of human ALDH1A3 has been solved by 
molecular replacement using the sheep liver ALDH1A1 atomic coordinates as a 
search model (PDB code: 1BXS)[45] and refined at a resolution of 2.9 Å. The final 
human ALDH1A3 model contains eight identical chains per asymmetric unit, 
arranged as two independent tetramers  and a total of 66 solvent molecules (Table 
1). In each monomer no electron density is present for the N-terminal portion and 
for the last four amino acids at the C-terminal region. In addition in all eight 
monomers are present some disorder and no electron density is detectable in 
different zone of the structure (Table 3).  
Table 3. Missing residues of all the eight monomers composing the asymmetric unit of human ALDH1A3 
crystals. 
hALDH1A3 
Monomer Missing residues (no ρ) 
 A 1-18, 508-512 
Tetramer 
ABCD 
B 1-22, 509-512 
ABCD C 1-20, 509-512 
 D 1-19, 508-512 
 E 1-22, 508-512 
Tetramer 
EFGH 
F 1-27, 338-343, 348-353, 386-394, 406-414 508-
512 EFGH G 1-28, 383-391, 404-411, 508-512 
 H 1-20, 509-512 
 
The height monomers of the asymmetric unit share the same conformation showing 
an r.m.s.d. of 0.44 Å after superposition based on all 475 Cα atoms. Tetramer 
ABCD exhibits a global better-defined electron density than the EFGH tetramer. 
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Each monomer composing the asymmetric unit binds one molecule of NAD, while 
electron density corresponding to product retinoic acid (REA) exhibits a better 
defined density in chains A, B, C and D. In summary our model is the first 
structure of human ALDH1A3 reported in complex with NAD and REA. The 
stereochemistry of the model has been assessed with the program PROCHECK[37] 
and 99% of protein residues fall in the favored regions of the Ramachandran plot.  
Overall structure of human ALDH1A3 
Tetramer  
The crystal structure of hALDH1A3 reveals the presences of two tetramers in the 
asymmetric unit with the four monomers intimately associated (Figure 2). 
Crystallographic data were supported by size exclusion chromatography that 
reveals an oligomeric state for recombinant enzyme consistent with a tetrameric 
quaternary structure in solution, as described for many ALDHs[46]. Indeed 
hALDH1A3 has a predicted molecular weight of 56 KDa and gel filtration 
experiment shows one defined peak corresponding to a native molecular mass of 
about 224 KDa (Figure 2). Moreover, the PISA analysis prediction[47] confirms that 
the favorite conformation of hALDH1A3 is a tetramer with an Assembled Surface 
Area (ASA) of 62658 Å2 and a Buried Surface Area (BSA) of 17769 Å2. In 
addition, the dimerization association, also predicted by PISA, is between chain A 
and B (BSA 2520 Å2) and chain C and D (BSA 2456 Å2). The secondary structures 
involved in the interaction surfaces (β5, α7, β18, β15, α13) contribute to the 
stability of the complex mainly with hydrogen bonds and few hydrophobic 
interactions. Three salt bridges between R84 - E426, R487 - E489, and R271 - 



















Figure 2. A) Cartoon representation of the biological tetrameric assembly of hALDH1A3 Chains A, B, C 
and D are colored in orange, blue, yellow and green, respectively. All the N-terminal of the monomer are 
flexible and exposed to the solvent, whereas the C-terminal are organized at the core of the tetramer B) Size 
exclusion chromatogram showing the elution peak of ALDH1A3 recombinant protein in solution. The elution 
volume corresponds to a molecular weight of 224 KDa, consistent with a tetrameric quaternary structure. 
Monomer 
Despite the assembly as homotetramer, each monomer of the human ALDH1A3 is 
independently able to convert one molecule of substrate to one molecule of product 
by reducing one NAD+. The structure analysis of hALDH1A3 monomer confirmed 
that the protein shares high homology of the overall structure across all classes of 
ALDHs. Human ALDH1A3 folds into 13 α-helices, 19 β-strands and connecting 
loops resulting in a molecular architecture with three functional domains (Figure 
3). The N-terminal NAD binding domain (L20-D149 and I171–G282), which 
characterizes the ALDH superfamily contains five-stranded parallel β-sheets (β9, 
β8, β7, β10 and β11). The C-terminal catalytic domain (G283–M482) is made by 
six-stranded parallel β-sheets (β15, β16, β13, β12, β17 and β18), and the 
oligomerization domain (K150–P170 and S483–L507) is defined by three-stranded 
antiparallel β-sheets (β5, β6 and β15). Both the NAD+ binding and the catalytic 































Figure 3. Crystal structure and topology of the secondary structure of hALDH1A3. The three dimensional 
structure is shown as cartoon representation with the N-terminal domain, the C-terminal domain, and the 
oligomerization domain colored in light orange, orange and red, respectively. The ligands NAD and REA are 
shown as white and green sticks, respectively. Beside the tertiary structure is reported the topology of the 
secondary assembly of the ALDH1A3 protein. 
 
The superposition of our model with human ALDH1A1 available structure (PDB: 
4WB9)[48] evidences a perfect correspondence of all secondary structures (r.m.s.d. 
of 0.84 Å for the 485 Cα). As well the superposition with the sheep liver ALDH1 
highlight the similarity with the isoenzyme used as search model (r.m.s.d. of 0.88 
Å for the entire polypeptide chain). Furthermore, ALDH1A3 shares high sequence 
similarity with other ALDHs with more than 70% amino acids identity with the 
human isozymes ALDH1A1 and ALDH1A2. The Figure 4 reports the alignment of 
the human ALDH1A3 with secondary structure information from PDB, with 
representative isoforms of the ALDH human superfamily. The sequence alignment 
was done with T-Coffee Expresso[49] and ESPript 3.0[50] confirming the high 
homology within ALDHs. The substrate selectivity of the different isozymes is 
ascribable to single amino acid mutations in the conserved regions and the 


































































Figure 4. Alignment of the human ALDH1A3 amino acids sequence with representative human ALDHs: 
ALDH1A1, ALDH1A2, ALDH2 and ALDH3A1. The secondary structure indications on top of the aligned 
amino acids refer to the hALDH1A3 PDB. Identical and similar amino acids are boxed in red and yellow, 
respectively. 
 
Retinoic acid and NAD+ binding site 
Our structural model highlights different conformations of REA and NAD+ in 
complex with the ALDH1A3 isoenzyme. In particular, in monomer D, REA is 
mimicking the substrate with the carboxyl group close to the catalytic C314. At the 
same time the nicotinic acid moiety of NAD+ is close to the active site like to 
accept the hydride from the thiohemiacetal intermediate. In monomer C, the 
retinoic acid is bound to the tunnel known to be the access for the substrates to the 
catalytic site. In parallel, NAD+ nicotinic ring move closest to the surface of the 
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Figure 5. Overview of retinoic acid and NAD in complex with ALDH1A3 chains C and D. The figure 
describes the key aspect of the different conformations of the ligands co-crystallized with the protein. In 
monomer D, NAD binds near the canonical hydride transfer conformation, at the meantime REA is mimicking 
the substrate with the carboxyl group positioned close to the catalytic C314. The conserved residue E280 is 
closer to C314 with which establish weak interactions. In monomer C, NAD is far from the catalytic site with 
the nicotinamide moiety exposed to the solvent at the surface of the protein. The REA binds through 
hydrophobic interactions close to the opening of the tunnel that leads to the catalytic site, while E280 move 
outside of the catalytic site leaving room for the release of the product. We speculate that the ternary complex 
of monomer C can describe a putative release mechanism of the ligands after the occurred catalysis. 
 
Architecture of the catalytic pocket in complex with REA 
The most important feature of our structure is the definition of the tunnel for the 
retinal substrate and the interactions of the natural product with conserved residues 
of the catalytic pocket. Our structural data confirm the prediction analysis on 
substrate binding made on sheep liver and human ALDH1A1 structures[45], [48]. In 
human ALDH1A3 the catalytic task is made on the left-hand side by helix α3 that 
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on the right-hand side by a surface loop (467 - 473) that precedes helix α13 near 
the oligomerization domain. The back of the tunnel is made up by helix α4 that is 
also the first α helix of the canonical Rossmann fold of the N-terminal domain. 
Helix α8 makes up the bottom of the substrate entrance tunnel, and originates from 
the catalytic domain, immediately preceding the active-site nucleophile (C314). 
The base of the tunnel comprises two β strands (β10, β11) (Figure 3). The first 
mechanism for selectivity adopted by ALDHs is the substrate access of the 
catalytic site, since the tunnel geometry is determinant for the specificity of ALDH 
isoforms. Precedent studies identified amino acids 124, 459 and 303 (based on 
ALDH2 sequence) as three signatures amino acids[51]. Our structural analysis 
confirmed that hALDH1A3 has the typical signature amino acids of ALDH1 
family: G136, L471 and T315 respectively in the position corresponding to 124, 
459 and 303. In particular, G136 is located at the entrance of the tunnel and its 
reduced steric bulk allows the entrance of large substrates. The steric occupancy of 
L471 positioned near to the access to the catalytic task is also determinant for 
ALDH1A3 selectivity. T315 lies next to reactive C314 and it is involved in the 
direct substrate interactions. In both the described conformations the β-ionone ring 
of REA doesn’t just sticks out from the tunnel but establishes contacts with the 
protein environment. The natural product binds to the protein through hydrophobic 
interactions with G136, R139, W189, L185, L471, N469 and I132 conserved 
residues (Figure 6). In particular the β-ionone ring of REA is positioned at the 
entrance of the substrate access tunnel and establishes π-π stacking contacts with 
W189, and Van der Waals interactions with T140 and R139 conserved residues 




















Figure 6. Hydrophobic residues involved in the binding of the product REA in complex with monomer C 
and monomer D. Ligplot+ v 1.4.5[39] representation was used to highlight the conserved interaction between 
the aliphatic REA and the hydrophobic residues G136, R139, W189, L185, L471, N469 and I132  in the 
catalytic pocket of chain C and D. Spoked arcs represent protein residues making nonbonded contacts with the 
ligand. The bold spoked arcs indicate protein residues that are in equivalent 3D positions when the two 
structural models are superposed.  
 
In monomer D the solvent-accessible area of the substrate task corresponds to 290 
Å2 and it is compatible with a tunnel volume able to host all-trans retinal. At the 
end of the tunnel the carboxyl group of REA was stabilized by the strictly 
conserved M186 and C314. The catalytic SG of C314 engaged hydrogen bond with 
the oxygen O2 of REA carboxylic group (2.98Å) while SD of M186 stabilizes the 
O1 (2.93Å). In details, we observed that the methyl group (CE) of M186 undergoes 
a rotation of about 45° in the presence of REA with respect to chain C 
conformation, favoring the formation of a hydrogen bond between sulphur and 
oxygen (Figure 7A). In monomer C the solvent-accessible area of the substrate 
access tunnel was measured in 310 Å2. The product REA is partially exposed to the 
solvent and the carboxyl group follows through to the exit from the tunnel by two 
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Figure 7. Representation of the main interactions within the two conformations of REA and the 
respective monomer. A) REA in complex with monomer D (white). The β-ionone ring establishes 
hydrophobic interactions with W189, T140 and R189, while the carboxyl group makes hydrogen bonds with 
C314, M186. B) REA in complex with monomer C (wheat). The β-ionone ring maintains the same 
hydrophobic interactions with W189, T140 and R189. The carboxyl group it is within interacting distance for 
hydrogen bonds with Q304 and H126. 
 
In addition we observed in our structure a double conformation of the strictly 
conserved E280 that acts like a general base and it is responsible of the activation 
of two water molecules essential for the reduction of the catalytic C314 and for the 
hydrolysis of the thioester intermediate. In the hALDH1A3 chain D, the E280 is in 
the “inside” position close to the C314 (3.69 Å), meanwhile in monomer C is in the 
“outside” position referring to the description by Muñoz-Clarez et al.[52] (Figure 5). 
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NAD+ binding at the N-terminal domain of hALDH1A3 
The N-terminal NAD+-binding domain of human ALDH1A3 enzyme, exhibits the 
typical ALDH cofactor-binding motif (β, α, β) that differs from the classical 
Rossmann fold generally involved in the NAD+ recognition[53]. Many ALDHs 
structures evidence the ability of the enzyme to bind a population of NAD 
conformers[54]. In our structure all the NAD+ molecules in complex with ABCD 
tetramer have traceable electron density for the adenine moiety and the 
pyrophosphates, whereas the nicotinamide ring of the cofactor is mobile. In the 
reported hALDH1A3 crystal structure, the adenine lies in a conserved hydrophobic 
pocket between helix α4 and strand β8, as described for the majority of human 
ALDHs in complex with NAD (PDB code: 4WB9, 1O00, 1BXS). In particular, the 
adenine moiety was taken in place through π-π stacking interaction with P238 and 
hydrophobic interaction with V261 (Figure 8). In all the NAD conformations in 
complex with the ALDH1A3 the NZ of K204 engaged an hydrogen bond with the 
oxygen O2B of the adenine ribose (2.05 Å in chain C), and the first phosphate 
group of NAD is stabilized by another hydrogen bond between the oxygen O1A 
and OG of S258 (2.80 Å in chain C) (Figure 8). The network of interactions 
described for the adenine and the pyrophosphates refers to all the molecules of 
NAD in complex with the hALDH1A3 protein, whereas for what concern the 
nicotinamide moiety we observed in our structure two different conformations in 
complex with monomers C and D. In the monomer D, the NAD+ nicotinamide 
group was oriented near the catalytic site at about 10 Å from the SG of catalytic 
cysteine C314. In this conformation the O2D of nicotinamide ribose is stabilized 
through an hydrogen bond with N7 of K364 (2.31 Å) and the O3D engaged 
hydrogen bonds with OE1 (2.80 Å) and NE2 (2.37 Å) of Q361. The carbamide 
group is stabilized through the binding between its N7N and OG1 of T259 (3.55 
Å), and between O7N and OE1 of E260 (2.97Å) (Figure 8A).  
 































Figure 8. Superposition on NAD conformations in complex with chain C and D. Residues from the two 
monomers are represented as sticks and colored in wheat for monomer C and in white for monomer D. A) The 
figure illustrates the superposition of the two conformations and the conserved residues that are involved in the 
stabilization and binding of the adenine moiety and the pyrophosphates. P238 and V261 stabilize through π-π 
stacking and hydrophobic interactions the adenine. K204 and S258 are involved in hydrogen bonds with 
adenine ribose and the pyrophosphate closer to the adenine. B) Conformation of NAD in complex with chain 
D. The K204 is within interacting distance for hydrogen bonds with the oxygen O2B of the adenine ribose 
(2.05 Å). The S258 make a hydrogen bond with the O1A of the first phosphate group of NAD (2.80 Å). The 
O2D and O3D of the nicotinamide ribose make hydrogen bonds with N7 of K364 (2.31 Å) and NE2 (2.37 Å) 
of Q361. C) The NAD conformation of chain C shares all the binding of adenine moiety described for chain D. 
While the O3D of the nicotinamide ribose contacts the NE2 of Q208 (2.31 Å) and the N7N of the 
carboxyamide engaged hydrogen bonds with OE1 (3.3 Å) of E65 of the symmetry mate of monomer A. 
In monomer C, by moving close to the surface of the protein, the nicotinamide 
moiety of NAD+ loose the network of interactions described before[55]. The O3D of 
nicotinamide ribose contacts the NE2 of Q208 (2.31 Å), while the N7N of the 
  Chapter 3 
 57 
carboxyamide in our crystal assembly is within hydrogen binding distance with 
OE1 (3.3 Å) of E65 of the symmetry mate of monomer A (Figure 8B, Figure 9). 
 Otherwise in chain C the position of the C4 of nicotinamide group is located 16.1 
Å far from the SG of catalytic cysteine C314, which is more than double the 
distance compared to the reported NAD conformations in complex with other 
ALDHs (1BXS, 4WB9) (Figure 9).  
 
 
Figure 9. Superposition of NAD in complex with chain C (green) with NAD from 4WB9 (grey) and 1BXS 
(wheat). The overlap of the three cofactors highlights the movement of the nicotinamide of NAD in the 
direction of the surface of monomer C. The C4 of the nicotinamide ring is 16.1 Å far from C314, while the 
nicotinamide ring of NAD from human or sheep ALDH1A1 is 6 Å from the same catalytic residue. The 
nicotinamide is stabilized through hydrogen bond with the OE1 (3.3 Å) of E65 belonging to the symmetry mate 
of monomer A. The experimental electron density map for NAD in complex with chain C is represented in 
blue. 
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CONCLUSIONS 
The human ALDH1A3 is a member of the cytosolic aldehyde dehydrogenase class 
1 family with a key role in vertebrate embryonic development. Indeed, the enzymes 
of the ALDH1A subfamily show high specificity for retinaldehyde, oxidizing it to 
the powerful differentiation factor retinoic acid (REA)[8]. The ALDH1A3 has the 
most efficient dehydrogenase activity towards all-trans-retinal with respect to the 
others two isoenzymes.  
In the present study we provide the first structural model of human recombinant 
ALDH1A3 in complex with NAD+ and REA. Moreover the authors introduce an 
exhaustive biochemical characterization of the human isozyme, including the first 
reported Thermofluor experiment for ALDHs. Our biochemical data highlights the 
specificity of ALDH1A3 for all-trans retinal and demonstrate that human 
ALDH1A3 has greater affinity for NAD+ supporting the assumption that in ALDHs 
the cofactor is the first molecule to bind to the enzyme[56]. In addition, our thermal 
shifts analysis shown accordance with precedent studies that identify the release of 
the oxidized product and the reduced cofactor as the rate-limiting steps in ALDH1s 
catalysis[57]. Our crystallographic study on human ALDH1A3 provides the first 
structure that describes an isoform of ALDH1A subfamily co-crystallized with the 
natural product. Retinoic acid has been described in two different conformations. In 
chain C, REA was detected at the exit of the tunnel leading to the catalytic site, 
picturing a ternary complex in which NAD+ is far from the catalytic site and REA 
is almost on the protein surface. In chain D, REA is at the end of the tunnel with 
the carboxyl group close to the catalytic C314, in a conformation that mimic the 
substrate. The comparison of the two conformations of REA highlights a rotation 
of the aliphatic chain around carbon C10 that brings the functional carboxyl group 
or close to the active site or in the exit tunnel near the enzyme surface. Previous 
studies on ALDH1A2 suggested that the interaction of long aliphatic substrates, 
such as all-trans retinal, with a disorder loop is a key mechanism for the disorder to 
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order transition that accompanies the retinal catalysis[58]. In ALDH1A3 structure in 
complex with REA, the electron density of the described disorder loop (N469-
L489) is well defined, confirming that the recognition of the substrate is linked to 
disorder/ordered transition of the loop. We can speculate that the different 
conformation of REA influences the NAD+ nicotinamide moiety movement. 
Indeed, the superposition between chain C and D of ALDH1A3 confirmed the 
“swing” of the nicotinamide ring. In particular, NAD+ in complex with monomer D 
was oriented near the catalytic site, 10 Å far from the SG of catalytic C314. 
Otherwise in monomer C, in which REA binds the enzyme close to the exit tunnel, 
the nicotinamide moiety moved away from the catalytic site in the direction of the 
protein surface, 16.4 Å far from C314. This conformation describes a new 
orientation of NAD+ that differs from the known conformers of NAD+ reported in 
ALDH structures. 
In summary our data provide a first comprehensive structural view of different 
conformations of NAD and REA bound to ALDH1A3. The structural analysis of 
the human enzyme in complex with its ligand, together with its biochemical 
characterization can be a valuable starting point for the rational base drug design of 
molecules potentially active as inhibitors. This data takes on even more importance 
in light of the latest findings that demonstrated an elevated expression of human 
ALDH1A3 in mesenchymal Glioma Stem Cells (Mes GSCs) with respect to other 
ALDHs, including human ALDH1A1. This findings underscores the importance of 
defining the ALDH isoenzymes responsible for the high ALDHs activity in each 
cancer type and provide compelling evidence in favor of the ALDH isoenzymes 
functioning as key molecules governing cell proliferation, survival and 
chemoresistance of CSCs. In this contest, the complete structural determination of 
hALDH1A3 is a critical issue for rational design of small molecules to be used as 
prognostic marker and diagnostic tools. 
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INTRODUCTION  
Aldehydes dehydrogenases (ALDHs) are NAD(P)+ dependent enzymes that 
functions as catalysts for the dehydrogenase oxidation of a wide spectrum of 
aldehydes into their corresponding carboxylic acids[1]. The human ALDH 
superfamily consists of 19 putatively functional genes located on different 
chromosomes and grouped by sequence identity[2]. ALDHs sharing more than 40% 
sequence identity belong to the same family, meanwhile isoforms exhibiting more 
than 60% amino acids identity, reside in the same subfamily[2]. ALDHs are 
ubiquitous and conserved enzymes, essential for the clearance of potentially toxic 
aldehydes[3]. The importance of ALDHs in human metabolism is not only defined 
to their action as detoxifying enzymes but includes their role as key metabolic 
regulators[4]. ALDHs catalyze the biosyntheses of physiologically relevant 
molecules such as retinoic acid, γ-aminobutyric acid and betaine which are 
involved in embryonic development and tissue differentiation (retinoic acid), 
neurotransmission (γ-aminobutyric acid) and osmosis (betaine)[1]. The three 
isozymes belonging to the ALDH1A subfamily (ALDH1A1, ALDH1A2 and 
ALDH1A3) are all involved in the metabolism of retinoic acid (REA), a 
morphogen molecule that regulates embryonic development and cellular 
proliferation and differentiation. The aldehyde dehydrogenase family 1 member A3 
(ALDH1A3, E.C. 1.2.1.5) catalyzes the oxidation of all-trans retinal to REA using 
NAD+ as cofactor. ALDH1A3 is an essential enzyme for nasal development and 
more general for the embryonic development[5], and it is expressed in fetal nasal 
mucosa, kidney, breast, stomach and salivary gland. ALDH1A3 through REA 
signaling pathway, is implicated in the development of eye, olfactory bulbs, hair 
follicles, forebrain and cerebral cortex[1]. The three isozymes display differences in 
substrate selectivity, although they all share the ability to convert retinal isomers to 
REA. ALDH1A1 has a substrate preference for aldehydes deriving from lipid 
peroxidation as well as retinaldehyde. ALDH1A2 shows the highest catalytic 
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efficiency for the conversion of 9-cis retinal to REA[6], whereas ALDH1A3, despite 
it is capable to catalyzes the oxidation of cis-retinal to REA, displays a higher 
specificity for all-trans retinal with 10-fold the efficiency of ALDH1A1 and 
ALDH1A2[7]. We have been demonstrated that ALDH1A3 assemblies as a 
homotetramer in solution, moreover the enzyme shares high homology of three-
dimensional global structure across all classes of ALDHs. ALDH1A3 folds in three 
functional domains namely, NAD+ binding domain, catalytic domain and 
oligomerization domain, and its structure has been solved in complex with NAD 
and REA. The catalytic mechanism adopted by ALDH involves highly conserved 
amino acids and proceed through five critical steps. After the protein binds to 
NAD+ cofactor[8], the active C302 (numbering based on mature ALDH2) is 
activated through a water-mediated proton abstraction by E268, than the thiolate of 
C302 performs a nucleophilic attack on the electrophilic aldehyde. The formation 
of the thiohemiacetal intermediate is concomitant with the hydride transfer to the 
pyrimidine ring of the cofactor. Finally the hydrolysis of the thioester allows he 
release of the carboxylic acid and the reduced cofactor[9]. Despite similarity in the 
global structure, high homology in secondary sequence and conserved mechanism 
of reaction, ALDHs process a wide spectrum of substrates, exploiting for their 
selectivity different molecular architectures of the catalytic pocket[10]. These 
differences in substrate selectivity have been exploited to develop inhibitors of 
ALDHs that have been reviewed recently[9]. Up to date none of the known ALDHs 
inhibitors have been demonstrated to be isoform selective. For example disulfiram 
(also known with the commercial name Antabuse) is known to inhibit more 
potently the ALDH1A1 instead of the putative target ALDH2[11], while DEAB has 
been demonstrated to be at the same time a classic substrate (ALDH3A1), a 
covalent inhibitor, (ALDH2 and ALDH1A2), and an intermediate between 
substrate and inhibitor (ALDH1A1, ALDH1A3, ALDH1B1, and ALDH5A1)[12]. 
One of the first successful research on the development of isoform specific 
inhibitors is described by Morgan et al. that identify two compounds selective 
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towards human ALDH1A1[10] The increasing studies on Cancer Stem Cells (CSCs) 
are drawing the attention of the scientific community on ALDH role in cancers. 
High ALDH1 expression and/or enzymatic activity are consolidate markers for 
CSCs detection[13]. At the meantime high ALDH1 activity is a useful molecular 
tool for selection of ALDH-positive CSCs through FACS analysis with 
ALDEFLUOR™ assay. Noteworthy, high ALDH activity in CSCs was observed 
during cyclophosphamide treatment and correlated with cytotoxic drug resistance 
of CSC population[15]. The critical role of ALDH in cancer metabolism is coming 
down to specific isoforms that are being scrutiny as potential prognostic marker for 
many cancers and are often predictive of worst outcome of the tumors[14]. Notably, 
ALDH1A3 is gaining more importance in CSCs biology. Marcato et al. found that 
was the overexpression of ALDH1A3, and not ALDH1A1, that was predictive of 
metastasis in breast cancer stem cells[16]. In 2014 Shao et al. demonstrated the 
importance of ALDH1A3 for the maintenance of non-small lung cancer stem 
cells[17], whereas Mao et al. in 2013 found that ALDH1A3 is overexpressed in 
mesenchymal Glioma Stem Cells (Mes GSCs)[18].  
The structure determination of hALDH1A3 in complex with NAD and REA 
provides the necessary tool for the rational design of small ligands. In this work we 
provide a first in silico screening of compounds potentially active as inhibitors 
against the human ALDH1A3 and the first high throughput screening to test the 
inhibiting efficiency of the selected small molecules. Overall the structure-based 
drug design, beside its role in discovering potential inhibitors for ALDH1A3, is an 
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MATERIALS AND METHODS 
Cloning, Expression and purification of human ALDH1A1 and ALDH1A3 
The full-length human ALDH1A1 and ALDH1A3 genes were PCR amplified and 
cloned into the destination vector pDEST17 (providing a N-term 6xHis tag) using 
pENTR/D-TOPO Invitrogen Gateway® recombinant technology according to 
manufacture’s protocol. The constructed plasmids were then transformed into E. 
coli BL21(DE3) (Novagen), and expressed in a 2xTY medium supplemented with 
Ampicillin (50 µg/ml). One liter of medium was inoculated with cells directly 
collected from overgrown 2xTY agar plates (Ampicillin 50 µg/ml) and incubated at 
37 °C to OD600 = 0.6, then cells were grown at 20ºC overnight. After cultures were 
harvested by centrifugation, cells were resuspended in 40 mL of lysis Buffer A (50 
mM Na2HPO4 pH 7.5, 300 mM NaCl, 1mM β-mercaptoethanol, 10 mM imidazole) 
supplemented with 250U of Benzonase nuclease, and then lysed by sonication on 
ice. After addition of protease inhibitor cocktail (100 µL), the lysate was clarified 
by centrifugation. Soluble fraction was loaded onto a Ni-NTA Superflow 5mL 
cartridge (Qiagen) equilibrated with 10 column volumes (CV) of Buffer A and 
washed with Buffer A supplemented with 50 mM imidazole until the absorbance at 
280 nm return to the baseline (15 CV). Then the recombinant protein was eluted 
with Buffer A supplemented with 250 mM imidazole by a linear gradient in 20 CV. 
Fractions containing the expected enzyme were pooled and concentrated to 5 
mg/ml with Merck Millipore Amicon Ultra-15 10 kDa. The pool was further 
purified by a gel filtration step on a HiPrep 16/60 Sephacryl 200 High Resolution 
column equilibrated in the same buffer containing 20 mM HEPES pH 7.5, 150 mM 
KCl, 1 mM β-mercaptoethanol, 0.5 mM EDTA. The resulting procedure allowed us 
to obtain pure and active hALDH1A1 and hALDH1A3. All the purification steps 
described above were performed using a BioRad BioLogic DuoFlow FPLC-
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systems. Concentrations were determined by Bradford assay, and sample purity 
was assessed by SDS-PAGE.  
In silico analysis for the virtual screening of a ALDH1A3 pharmacophore 
The amino acids describing the catalytic pocket of ALDH1A3 have been identified 
as target for the design of small ligands potentially active as inhibitors. The 
pharmacophore features were identified with the online tool ZINCpharmer[19] 
directly form structural information of ALDH1A3 in complex with the ligand 
retinoic acid. ZINCpharmer recognizes and ranks those clusters of residues that 
define a binding site and provide an initial target for rational small-molecule 
design. ZINCpharmer identifies hydrophobic, hydrogen bond donor/acceptor, 
positive/negative ions and aromatic features that are critical for the interaction 
between the ligand and the receptor. The resulting pharmacophoric structural 
features, including the search radius and the steric limits determined by the 
geometry of the catalytic site, defined the pharmacophore models that were used to 
screen the purchasable compounds from the ZINC library (176 million conformers 
of 18.3 million compounds)[20]. The screening of the ZINC library returned a list of 
commercially available molecules that should satisfy the predicted contacts and 
receptor recognition preferences.  
The compounds of the first in silico screening were analyzed for their affinity for 
ALDH1A3 with smina[21], a fork of the AutoDock[22] program. A small, highly 
enriched set of sixteen compounds was selected by applying the expertise of the 
authors. Hot spots residues for selectivity of the docked compounds were 
confirmed by superposition[23] of the ALDH1A3 (unpublished) structures with 
human ALDH2 (PDB: 3N80), ALDH3A1 (PDB: 3SZA[24]) and ALDH1A1 (PDB: 
4WJ9[25]) that are representative ALDH isoforms and putative off-targets of the 
small ligands. 
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High-throughput screening for the identification of ALDH1A3 hits 
The previously reported continuous spectrometric assay for ALDH1A3 [to be 
published] was adapted to support a high throughput screening, and optimized to 
suit Corning ® 96-well format plate. For ALDH1A3 inhibition test, 200 µl reaction 
mixture containing 20 mM Tris HCl pH 8.0, 1 mM β-mercaptoethanol, 150 mM 
KCl, 100 µM NAD+ and 20 µM all-trans retinal, was set up in a Corning® 96 Well 
Clear Flat Bottom UV-Transparent Microplate.  
Reactions were started by the addition of 2.6 µM pure recombinant ALDH1A3. 
Change in absorbance at 340 nm (εNADH= 6220 M−1 cm−1) was monitored for 30 
min in a BioTek ® Synergy 2 Multi-Mode Reader at 25 °C.  
The ALDH1A1 spectrometric assay to test selectivity of chosen compounds was 
identical to hALDH1A3 assay with the only difference of 200 µM acetaldehyde 
used as substrate. 
Compounds chosen from virtual screen ZINC library collection based on their 
predicted potency on ALDH1A3 were dissolved in DMSO and tested at 100 µM in 
triplicates. The compounds with more than 50% inhibition were chosen for further 
confirmation using six points dose response concentration ranging from 500 µM 
down to 0.5 µM. The concentration of inhibitor (IC50) required to reduce the 
fractional enzyme activity to half of its initial value in the absence of inhibitor by 
the selected compound was calculated plotting the enzyme fractional activity 
against the logarithm of inhibitor concentration, and fitting the curves to a dose 
response curve (Eq.1): 
y=min+ ((max-min)/(1+10(LogIC50-x)))   (Eq. 1) 
In which y is the fractional activity of the enzyme in the presence of inhibitor at 
concentration [I], max is the maximum value of y observed at [I]= 0, and min is the 
minimum limiting value of y at high inhibitor concentrations. Results of the high 
throughput screening were analyzed with Sigmaplot (Systat Software, San Jose, 
CA) and GraphPad Prism 6.0e. 
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RESULTS AND DISCUSSION 
In silico virtual screening of small molecules 
Up to date there are no available ALDH inhibitors that are specific for ALDH1 
subfamily isoforms. The development of a selective compound able to target the 
human ALDH1A3 is a difficult challenge that needs the integrated approach of 
structural studies and in silico drug design. The resulting pharmacophore has to 
distinguish between a high number of ALDH isoforms with high similarity in 
secondary and tertiary structures. We thought that the affinity of most the ALDHs 
for different substrates could be exploited for the design of a selective molecule. 
The geometry of the substrate access tunnel has a central role in ALDHs 
specificity[26], since that the catalytic pocket is the ideal target for the in silico 
screening of small ligand with potential inhibiting action. The rational design of an 
ALDH1A3 pharmacophore is necessary to identify a ligand that can discern among 
the same subfamily enzymes. All the ALDH1A isozymes are able to catalyze the 
conversion of retinal to retinoic acid, but they show preferences for different 
isomer of retinal, implying some diversity in the catalytic site (i.e. ALDH1A3 has 
major affinity for all-trans retinal)[7]. 
Identification of pharmacophoric features in ALDH1A3 structure 
The three isoforms belonging to ALDH1A subfamily share more than 60% 
sequence identity, in details ALDH1A3 have 71% amino acids identity with 
ALDH1A1 and 72% identity with ALDH1A2[27]. The three sequences were aligned 
in T-Coffee Expresso[28], [29] with information on the topology of the secondary 
structure referred to the ALDH1A3 structure edited according to ESPript3[30]. The 
resulting alignment (Figure 1) underlines the high homology between the isozymes 
and the difficulties to identify critical amino acids target for the inhibitors. It is of 
our interest to find a compound that can discern in particular between ALDH1A1 
and ALDH1A3, considering the high expression of the two  
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isoforms in many CSCs, whereas high expression of the 1A2 isoform has not been 
related to solid tumor or CSCs[31].  
 
Figure 1. Sequence alignment of the three isoforms (UniProt ID) of ALDH1A subfamily. Aligned 
sequences of ALDH1A3 (P47895), ALDH1A1 (P00352), ALDH1A2 (O94788) (4). Red boxes highlight the 
residues conserved for all the isoforms; yellow boxes indicate residues conserved between two isozymes. The 
topology of the secondary structure refers to the unpublished ALDH1A3 PDB. The sequences alignment was 
performed using T-Coffee Expresso online tool[28], [29] and sequence information are edited according to the 
Espript3[30] notation conservation. 
The pharmacophore features that were satisfied for the in silico screening of small 
molecules with inhibiting potential are described in Figure 2. The superposition of 
ALDH1A3 three-dimensional structure (not published) to ALDH1A1 (PDB: 
4WJ9), ALDH2 (PDB: 3N80) and ALDH3A1 (PDB: 3SZA) structures allowed us 
to confirm the hot spots and the key residues critical for selectivity (Figure 3). The 
overlap of ALDH1A3 with ALDH2 and ALDH3A1 draw attention to the different 
architecture of the substrate access tunnels. ALDH2 and ALDH3A1 have two 
bulky amino acids located at the entrance and in the middle of the pocket, 
respectively the M124 and F292 for ALDH2, and the Y65 and the W233 for 
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ALDH3A1, which build a narrow tunnel accessible by small substrates such as 
acetaldehyde (Figure 3A).  
 
 
Figure 2. ZINCPharmer identification of pharmacophoric features for ligand-receptor interaction. The 
pharmacophore model needs to satisfy the selective interacting forces relevant for a putative pharmacological 
activity. The figure describes the binding site with the pharmacophoric points that are critical for the interaction 
within the small ligand and the receptor. The ALDH1A3 structure is reported in orange and the interacting 
forces representation follows the legend reported on the figure. 
 
Figure 3. A) Superposition of ALDH1A3 structure (orange) with ALDH2 (magenta, PDB: 3N80) and 
ALDH3A1 (cyan, PDB: 3SZA). The green dot lines circle the bulky residues that in ALDH2 and ALDH3A1 
occupy the access tunnel for the substrate. The yellow dot line and the grey dot line evidence the oxygen and 
the hydrogen of T315 that are possible target for hydrogen bond interaction with the inhibitor. B) Overlap of 
ALDH1A3 and ALDH1A1 (green PDB: W4J9). The superposition of the two ALDHs evidences the residues 
target for selectivity between the two isozymes. N469 and T315 are the two amino acids targeted as potential 
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On contrary the ALDH1A3 exhibits at the corresponding residue positions a G136 
and a Q303 that are amino acids with smaller side chains, building an open 
catalytic pocket accessible to larger substrate such as retinal. The structural analysis 
of ALDH isoforms at issue identifies the not conserved T315 as an interesting 
target for the design of a selective inhibitor. The T315 is located just next to the 
highly conserved catalytic C314 (C302 in the ALDH2 numbering) and it should be 
selective not only against ALDH2 and ALDH3A1 but also against the isozyme 
ALDH1A1. The geometry of the access tunnel cannot be a discriminant for 
selectivity against ALDH1A1. The docked compound needs to target the few 
amino acids that are not conserved and not similar between the catalytic sites of the 
two isoforms. The first target residue is exactly the hydrophilic T315 that have 
opposite properties compared to hydrophobic I304 in ALDH1A1. The second 
target residue is N469 of ALDH1A3 that corresponds to a G458 in the ALDH1A1 
(Figure 3B). Both the identified residues are at the meantime hydrogen donor and 
acceptor, being available for hydrogen bonds with the suitable pharmacophore. 
Primary in silico virtual screening gave 16 resulting hits of commercially available 
molecules that are potential inhibitors of human ALDH1A3. 
High throughput screening of potential inhibitors  
All the hits were tested for inhibition on pure recombinant ALDH1A3 as described 
in materials and methods. Out of the 16 predicted hits, compounds 1, 3, 9 and 11 
were responsible of 50% or more inhibition towards ALDH1A3 activity and were 
taken in account for further investigation (Figure 4). Out of the selected compounds 
only the molecules 3 and 9 gave reproducible and reliable data for half maximal 
inhibitory concentration (IC50) calculation. Compounds 1 and 11 evidence 
solubility problems or interference with the 340 nm wavelength emissions of 
NADH used to calculate the ALDH1A3 enzymatic activity, making difficult to 
obtain reliable data on a dose-response curve by spectrometric assay. Compounds 3 
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and 9 were tested at different concentrations in presence of natural substrate all-
trans retinal and NAD+ cofactor.  
 
Figure 4. Screening of the 16 hits resulting from the ZINC library virtual screen. The commercially 
available compounds were tested for inhibition against ALDH1A3 specific activity. Data for compound 
number 4 are not available due to solubility problems of the molecule. The inhibition was initially estimated as 
the percentage of residual fractional activity of the enzyme with 100 µM inhibitor concentration and compared 
with the ALDH1A3 activity. Compounds 1, 3, 9, 11 exhibited more than 50% inhibition and were considered 
for further investigations. 
The dose-response curve for antagonist number 3 and 9 versus human ALDH1A3 
allowed us to calculate an IC50 of 21 ± 2 µM and 52 ± 1.4 µM, respectively (Figure 
5). The compounds were tested also as inhibitors against ALDH1A1 activity. 
Preliminary data were collected by measuring the ALDH1A1 specific activity in 
presence of 50 µM of molecule 3 and 9 with fixed concentration of NAD+ and 
acetaldehyde as substrate. The compounds showed almost no inhibition towards 
























Inhibition on hALDH1A3 at 100 µM




Figure 5. A) IC50 calculation for compounds 3 and 9 on pure recombinant human ALDH1A3. The plot of 
the logarithm of inhibitor concentration versus the ratio of the velocity to initial velocity was fitted with four-
parameter sigmoidal curve equation (Eq.1). The IC50 for compound 3 was calculated as 21 ± 2 µM with an R= 
0.96. The IC50 for compound 9 was calculated as 52 ± 1.4 µM with an R= 0.97 
 
 
Figure 6. Inhibition of compounds 3 and 9 at 50 µM concentration on ALDH1A1 specific activity. The 
histogram is the result of the mean of three independent measurement reported as percentage of specific 
activity. ALDH1A1 maintain 92% of specific activity after inhibiting action of compound 3 and 85% of 
specific activity after inhibiting action of compound 9. 
 
CONCLUSIONS 
The structure-based drug design is an essential tool for the identification and the 
optimization of a lead compound, which is the first critical issue in the drug 



























Inhibition by compounds 3 and 9 at 50 µM on hALDH1A1
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The rational design of pharmacophores needs the structure determination of the 
biological target to identify hot spots of the protein critical for its catalytic 
mechanism or for the interaction with its ligands. The analysis of the X-ray 
structure of human ALDH1A3 in complex with its natural ligands and the 
comparison with other ALDHs, potential off-target of the compound, was essential 
for the successful results of the first in silico virtual screening. By screening only 
sixteen commercially available hits resulting from the virtual screening, we were 
able to obtain interesting preliminary data on selective compounds with inhibiting 
action. Although we are still far from the development of a potential inhibitor with 
pharmaceutical activity and therapeutic prospective, the selectivity of the molecules 
3 and 9 for ALDH1A3 towards ALDH1A1 lays good basis for the identification of 
a pharmacophore model. The identified compounds represent a good starting 
scaffold for the design and the chemical synthesis of further molecules with the 
objective for the identification of a lead compound with specificity for ALDH1A3 
isoform.  
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The human ALDH1A3 is a key enzyme of the retinoid metabolism in which it 
catalyzes the oxidation of retinaldehyde to retinoic acid (REA), a key signaling 
molecule for embryonic development and tissue differentiation[1]. High expression 
and activity of ALDH1A3 has been identified in different Cancer Stem Cells 
including Glioma Stem Cells[2], [3], [4]. In particular, overexpression of human 
ALDH1A3 was detected in mesenchymal GSCs of High Grade Gliomas (HGGs)[4], 
which are highly infiltrative and aggressive brain cancers characterized by poor 
prognosis (5 years survival < 5%), resistance to chemotherapy and recurrence after 
neurosurgery. This dramatic picture for grade III and grade IV gliomas highlight 
the necessity of a complete understanding of glioblastoma molecular bases that 
cannot discern from the understanding of Glioma Stem Cells biology. 
In the present study we provide the first structural model of human recombinant 
ALDH1A3 in complex with NAD+ and REA and an exhaustive biochemical 
characterization of the human isozyme, including the first reported thermofluor 
experiment. 
The analysis of the biochemical and biophysical observations on human 
ALDH1A3 supports the assumption of an ordered reaction mechanism on which 
the cofactor is the first molecule to bind the enzyme [5], as evidenced by the high 
affinity of the enzyme for NAD+. The increased Tm of ALDH1A3 in complex with 
the reduced cofactor NADH and the product REA is the result of an enhancement 
in the global stability of the enzyme. These thermal shift data are in accordance 
with the work of Rodríguez-Zavala et al. that identifies the release of the oxidized 
product and the reduced cofactor as the rate-limiting step in ALDH1 catalysis[6]. 
The human ALDH1A3 is the first structure that describes an isoform of the 
ALDH1A subfamily co-crystallized with the natural product. REA has been co-
crystallized in complex with ALDH1A3 in two different conformations. In chain C, 
the ligand was fitted in the electron density detected at the “exit” of the tunnel 
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leading to the catalytic site. The ternary complex of the protein in presence of REA 
and NAD+ shows a global conformation in which the product is close to the protein 
surface, at the meantime the nicotinamide ring of NAD is exposed to the solvent, 
far from the catalytic C314. Instead in ALDH1A3 chain D, the carboxyl group of 
REA is located at the end of the access tunnel in a conformation that mimic the 
substrate, within interacting distance with the catalytic C314.  
Previous studies on rat ALDH1A2 suggest that the interaction of long aliphatic 
substrates with a disorder loop (~ aa 457 - aa 477, based on ALDH2), part of the 
substrate access tunnel, is a key mechanism for the disorder to order transition that 
accompanies the retinal catalysis[7]. In the reported ALDH1A3 structure in complex 
with REA, the electron density of the loop involved in substrate recognition (N469-
L489) is well defined. Interestingly in both REA conformations the β-ionone ring is 
within interacting distances with L469, A470 and Q471 of the loop, supporting the 
hypothesis that the interaction of this loop with the substrate, or in our case with 
the product that mimic the substrate, is suitable with a disorder/ordered transition, 
necessary for catalysis. The geometry of the substrate access tunnel is also critical 
for substrate selectivity[8]. ALDH1A3 has the typical signature amino acids of 
ALDH1 subfamily catalytic pocket. The architecture of the catalytic site of 
ALDH1A3 is determined by a G136 located at the opening of the tunnel that 
allows the entrance of large substrates, a L471 positioned at the funnel of the 
access to the catalytic site that can accommodate large substrates and a T315 at the 
bottom of the active site, next to reactive C314, that can be involved in direct 
interactions with the substrate. 
NAD+ appears to bind to ALDHs with a high degree of conformational 
heterogeneity, due to the rotation of nicotinamide about the glycosidic bond[9], [10]. 
In the reported ALDH1A3 X-ray crystal structure, we described a new NAD+ 
isomer that differs from the known conformers of the cofactor in complex with 
ALDH (PDB: 1BXS, 4WB9). The superposition of NAD from ALDH1A3 chain C 
with known conformation of the cofactor from other ALDH structures (1BXS, 
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4WB9), highlight the “swing” of the nicotinamide ring close to the surface of the 
protein. The novel isomer of NAD maintains the network of interactions that 
stabilizes the adenine and the pyrophosphates, while the nicotinamide ring is 
stabilized by the E65 of the symmetry mate of monomer A, that is next to 
monomer C in our crystal assembly. Notably, when REA mimics the substrate in 
chain D, the nicotinamide is likely to be located close to the catalytic site. Whereas, 
when REA binds close to the entrance of the substrate access tunnel that in this 
case exploit the function of “exit tunnel”, the nicotinamide of the cofactor showed 
a defined electron density next to the surface of the protein, leaving room at the 
catalytic site as consequence of the occurred hydrolysis. Overall the structural 
investigation on hALDH1A3 in complex with NAD and REA, together with its 
biochemical characterization, provides the experimental critical issue to develop 
novel potential selective inhibitors that can be used as chemical tools to investigate 
the role of the ALDH1A3 isoform in normal cells and cancer stem cells.  
A first structure-based in silico screening of small molecules with potential activity 
as inhibitors on ALDH1A3 was performed in the present research. The analysis of 
the pharmacophoric features that need to be satisfied for the building of a 
pharmacophore model were determined through ZINCPharmer and confirmed by 
structural analysis of the ALDH1A3 in complex with its ligand. The superposition 
of ALDH1A3 with representative ALDHs (ALDH3A1, ALDH2) and with the 
human isozyme ALDH1A1 confirmed the identification of N469 and T315 as hot 
spots for the rational design of small molecule selective mainly towards 
ALDH1A1. In addition, the geometry of the catalytic site is exploited for the 
selectivity against ALDH3A1, ALDH2 and all the ALDH isoforms that process 
medium and small aldehydes. Sixteen compounds, resulting as the best hits from 
the virtual screening, were tested for inhibition on ALDH1A3 with a spectrometric 
high throughput screening. Out of sixteen hits, four compounds showed more than 
50% inhibiting activity at 100 µM. Among the selected molecules compounds 3 
and 9 showed a promising IC50 of 21 and 52 µM, respectively. Considering that the 
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two hits are the result of a preliminary screening between only sixteen 
commercially available molecules, the compounds 3 and 9 are interesting starting 
points for the development of more potent inhibitors. Moreover the two ligands 
seem to be selective on ALDH1A3 towards ALDH1A1, which are the two critical 
ALDH isoenzymes overexpressed in CSCs. The structure determination of 
hALDH1A3 in complex with NAD and REA among with the rational design of 
small molecules are potent tools for the identification of lead compounds and for 
the development of an isoform specific probe that would be of interest for 
prognosis or diagnostic purposes. 
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